1
|
Ollivier L, Laprie A, Jouglar E, Claude L, Martin V, Muracciole X, Padovani L, Supiot S, Escande A. [Characteristics of radiotherapy for adolescents and young adults]. Cancer Radiother 2023; 27:736-745. [PMID: 38652674 DOI: 10.1016/j.canrad.2023.08.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2023] [Accepted: 08/02/2023] [Indexed: 04/25/2024]
Abstract
Radiotherapy for adolescents and young adults is complex in several aspects. The population is very heterogeneous and has characteristics derived from both paediatric and adult populations both in terms of pathology (anatomical pathology, response to treatment) and the patient's physical, biological and psychological characteristics. This article reviews the characteristics to be taken into account in adolescent and young adult patients radiotherapy and more particularly in some of the most common diseases.
Collapse
Affiliation(s)
- L Ollivier
- Département de radiothérapie, institut de cancérologie de l'Ouest (ICO), Saint-Herblain, France
| | - A Laprie
- Département d'oncologie-radiothérapie, oncopole institut Claudius-Regaud, institut universitaire du cancer de Toulouse, université Toulouse III, Toulouse, France
| | - E Jouglar
- Département de radiothérapie, institut Curie, université Paris Science et Lettres, Paris, France
| | - L Claude
- Département de radiothérapie, centre Léon-Bérard, Lyon, France
| | - V Martin
- Département d'oncologie-radiothérapie, Gustave-Roussy, Villejuif, France
| | - X Muracciole
- Département d'oncologie-radiothérapie, Assistance publique-hôpitaux de Marseille, CHU La Timone, CHU Nord, Marseille, France
| | - L Padovani
- Département d'oncologie-radiothérapie, Assistance publique-hôpitaux de Marseille, CHU La Timone, CHU Nord, Marseille, France
| | - S Supiot
- Département de radiothérapie, institut de cancérologie de l'Ouest (ICO), Saint-Herblain, France
| | - A Escande
- Département de radiothérapie, centre Léonard-de-Vinci, Dechy, France; Laboratoire CRIStAL, UMR 9186, université de Lille, Villeneuve-d'Ascq, France.
| |
Collapse
|
2
|
Aleman BMP, Ricardi U, van der Maazen RWM, Meijnders P, Beijert M, Boros A, Izar F, Janus CPM, Levis M, Martin V, Specht L, Corning C, Clementel E, Raemaekers JM, André MP, Federico M, Fortpied C, Girinsky T. A Quality Control Study on Involved Node Radiation Therapy in the European Organisation for Research and Treatment of Cancer/Lymphoma Study Association/Fondazione Italiana Linfomi H10 Trial on Stages I and II Hodgkin Lymphoma: Lessons Learned. Int J Radiat Oncol Biol Phys 2023; 117:664-674. [PMID: 37179034 DOI: 10.1016/j.ijrobp.2023.05.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2023] [Revised: 04/29/2023] [Accepted: 05/05/2023] [Indexed: 05/15/2023]
Abstract
PURPOSE Involved node radiation therapy (INRT) was introduced in the European Organisation for Research and Treatment of Cancer/Lymphoma Study Association/Fondazione Italiana Linfomi H10 trial, a large multicenter trial in early-stage Hodgkin Lymphoma. The present study aimed to evaluate the quality of INRT in this trial. METHODS AND MATERIALS A retrospective, descriptive study was initiated to evaluate INRT in a representative sample encompassing approximately 10% of all irradiated patients in the H10 trial. Sampling was stratified by academic group, year of treatment, size of the treatment center, and treatment arm, and it was done proportional to the size of the strata. The sample was completed for all patients with known recurrences to enable future research on relapse patterns. Radiation therapy principle, target volume delineation and coverage, and applied technique and dose were evaluated using the EORTC Radiation Therapy Quality Assurance platform. Each case was reviewed by 2 reviewers and, in case of disagreement also by an adjudicator for a consensus evaluation. RESULTS Data were retrieved for 66 of 1294 irradiated patients (5.1%). Data collection and analysis were hampered more than anticipated by changes in archiving of diagnostic imaging and treatment planning systems during the running period of the trial. A review could be performed on 61 patients. The INRT principle was applied in 86.6%. Overall, 88.5% of cases were treated according to protocol. Unacceptable variations were predominately due to geographic misses of the target volume delineations. The rate of unacceptable variations decreased during trial recruitment. CONCLUSIONS The principle of INRT was applied in most of the reviewed patients. Almost 90% of the evaluated patients were treated according to the protocol. The present results should, however, be interpreted with caution because the number of patients evaluated was limited. Individual case reviews should be done in a prospective fashion in future trials. Radiation therapy Quality Assurance tailored to the clinical trial objectives is strongly recommended.
Collapse
Affiliation(s)
- Berthe M P Aleman
- Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
| | | | | | - Paul Meijnders
- Department of Radiotherapy, Iridium Network, Centre for Oncological Research of the University of Antwerp, Antwerp, Belgium
| | - Max Beijert
- Department of Radiotherapy, University Medical Center Groningen, Groningen, Netherlands
| | - Angela Boros
- Radiation Oncology Department, Center Hospitalier Lyon Sud, Pierre Benite, France
| | - Françoise Izar
- Department of Radiotherapy, Institut universitaire du cancer de Toulouse, Toulouse, France
| | - Cécile P M Janus
- Department of Radiotherapy, Erasmus MC Cancer Institute, Rotterdam, Netherlands
| | - Mario Levis
- Department of Oncology, University of Turin, Turin, Italy
| | - Valentine Martin
- Department of Radiotherapy, Institut Gustave Roussy, Villejuif, France
| | - Lena Specht
- Department of Oncology, Rigshospitalet, University of Copenhagen, Denmark
| | - Coreen Corning
- The European Organisation for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium
| | - Enrico Clementel
- The European Organisation for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium
| | - John M Raemaekers
- Department of Internal Medicine, Rijnstate Hospital, Arnhem, Netherlands
| | - Marc P André
- Department of Hematology, CHU UCL Namur, Yvoir, Belgium
| | - Massimo Federico
- CHIMOMO Department, University of Modena and Reggio Emilia, Modena, Italy
| | - Catherine Fortpied
- The European Organisation for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium
| | - Theodore Girinsky
- Department of Radiotherapy, Institut Gustave Roussy, Villejuif, France
| |
Collapse
|
3
|
Gueiderikh A, Ung M, Lazarovici J, Danu A, Ghez D, Saleh K, Dragani M, Noël N, Bigenwald C, Willekens C, Ribrag V, Michot JM, Martin V. Incidence, characteristics, management and outcome of patients with follicular lymphoma with tumor epidural compression, a study on 22 cases. Cancer Radiother 2023; 27:370-375. [PMID: 37156711 DOI: 10.1016/j.canrad.2023.04.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2023] [Revised: 03/30/2023] [Accepted: 04/15/2023] [Indexed: 05/10/2023]
Abstract
PURPOSE Follicular lymphoma (FL) is one of the most common lymphoma. Occasionally, FL is associated with tumoral epidural compression and management of these patients remain poorly codified. This study aims to report incidence, clinical characteristics, management and outcomes of patients with FL and tumoral epidural compression. MATERIAL AND METHODS Observational, retrospective cohort study of adult patients with FL and epidural tumor compression, treated in a French Institute over the last 20 years (2000-2021). RESULTS Between 2000 and 2021, 1382 patients with FL were followed by the haematological department. Of them, 22 (1.6%) patients (16 men and 6 women) had follicular lymphoma with epidural tumor compression. At epidural tumor compression occurrence, 8/22 (36%) patients had a neurological clinical deficit (motor, sensory or sphincter function) and 14/22 (64%) had tumor pain. All patients were treated with immuno-chemotherapy; the main regimen being used was R-CHOP plus high dose IV methotrexate in 16/22 (73%) patients. Radiotherapy for tumor epidural compression was performed in 19/22 (86%) patients. With a median follow-up of 60 months (range=[1-216]), 5 year local tumor relapse free survival was achieved in 65% (95% CI 47-90%) of patients. The median PFS was of 36 months (95% CI 24-NA) and 5 years OS estimate was 79% (95% CI 62-100%). Two patients developed a relapse at a second epidural site. CONCLUSION FL with tumoral epidural compression reached 1.6% of all FL patients. Management based on immuno-chemotherapy with radiotherapy appeared to produce comparable outcomes with the general FL population.
Collapse
Affiliation(s)
- A Gueiderikh
- Radiation therapy department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France.
| | - M Ung
- Radiation therapy department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - J Lazarovici
- Hematology department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - A Danu
- Hematology department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - D Ghez
- Hematology department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - K Saleh
- Hematology department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - M Dragani
- Hematology department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - N Noël
- Internal medicine department, hôpital Bicêtre, AP-HP, 78, rue du Général-Leclerc, 94270 Le Kremlin-Bicêtre, France
| | - C Bigenwald
- Hematology department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - C Willekens
- Hematology department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - V Ribrag
- Hematology department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - J-M Michot
- Hematology department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - V Martin
- Radiation therapy department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| |
Collapse
|
4
|
Karam E, Tabutin M, Mastier C, Crignis LD, Peyrat P, Martin V, Badon F, Muller X, Meeus P, Rivoire M, Dupré A. Curative-intent treatment of pulmonary metastases from colorectal cancer: A comparison between imaging-guided thermal ablation and surgery. J Surg Oncol 2023; 127:183-191. [PMID: 36169242 DOI: 10.1002/jso.27108] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2022] [Revised: 08/19/2022] [Accepted: 09/16/2022] [Indexed: 02/04/2023]
Abstract
BACKGROUND Pulmonary metastases (PM) are the most frequent extra-abdominal metastases from colorectal cancer. Lung resection and imaging-guided thermal ablation (IGTA) are used as curative-intent treatment. We compared the outcomes of patients with PM, treated with resection or ablation. METHODS We retrospectively analyzed data from patients who underwent surgery or IGTA for colorectal PM between April 2011 and November 2020. Surgery was performed for peripheral PM and IGTA for deep-located PM not in contact with major vessels. Patients who had both procedures were excluded. Patients were compared using propensity score matching (PSM) analysis, stratified according to number, size, and unilaterality of PM. RESULTS One hundred and fourty-six patients were included, 65 (44.5%) underwent surgery and 81 (55.5%) underwent IGTA. After PSM analysis, each group contained 46 patients. IGTA patients had a lower morbidity rate (13.1% vs. 15.2%, p = 0.028) and a shorter length of stay (5.13 vs. 2.63 days, p < 0.001). Oncological outcomes were similar in both groups with 5-year OS of 80% and 5-year progression-free survival (PFS) of 30% (p = 0.657 and p = 0.504, respectively) with similar recurrence patterns. CONCLUSION Lung resection and IGTA seem to have similar oncologic outcomes for both OS and PFS. IGTA could be an alternative effective treatment for small PM, whenever technically feasible.
Collapse
Affiliation(s)
- Elias Karam
- Department of Surgical Oncology, Centre Léon Bérard, Lyon, France
| | - Mayeul Tabutin
- Department of Surgical Oncology, Centre Léon Bérard, Lyon, France
| | | | - Lucas De Crignis
- Department of Surgical Oncology, Centre Léon Bérard, Lyon, France
| | - Patrice Peyrat
- Department of Surgical Oncology, Centre Léon Bérard, Lyon, France
| | - Valentine Martin
- Department of Surgical Oncology, Centre Léon Bérard, Lyon, France
| | - Floriane Badon
- Department of Surgical Oncology, Centre Léon Bérard, Lyon, France
| | - Xavier Muller
- Department of Surgical Oncology, Centre Léon Bérard, Lyon, France
| | - Pierre Meeus
- Department of Surgical Oncology, Centre Léon Bérard, Lyon, France
| | - Michel Rivoire
- Department of Surgical Oncology, Centre Léon Bérard, Lyon, France.,Univ Lyon, Université Lyon 1, Centre Léon Bérard, INSERM, LabTAU, Lyon, France
| | - Aurélien Dupré
- Department of Surgical Oncology, Centre Léon Bérard, Lyon, France.,Univ Lyon, Université Lyon 1, Centre Léon Bérard, INSERM, LabTAU, Lyon, France
| |
Collapse
|
5
|
Abstract
A third of children with cancer receive radiotherapy as part of their initial treatment, which represents 800 paediatric irradiations per year in France carried out in 15 specialized centres approved on the recommendations of the French national cancer institute in decreasing order of frequency, the types of cancer that require irradiation are: brain tumours, neuroblastomas, Ewing's sarcomas, Hodgkin's lymphomas, soft tissue sarcomas including rhabdomyosarcomas, and nephroblastomas. The treatment guidelines follow the recommendations of the French society for childhood cancers (SFCE) or the French and European prospective protocols. The therapeutic indications, the technical and/and ballistic choices of complex cases are frequently discussed during bimonthly paediatric radiotherapy technical web-conferences. All cancers combined, overall survival being 80%, long-term toxicity logically becomes an important concern, making the preparation of treatments complex. The irradiation methods include all the techniques currently available: 3D conformational irradiation, intensity modulation radiation therapy, irradiation under normal or hypofractionated stereotaxic conditions, brachytherapy and proton therapy. We present the update of the recommendations of the French society for radiation oncology on the indications, the technical methods of realization and the organisation and the specificities of paediatric radiation oncology.
Collapse
Affiliation(s)
- A Laprie
- Département d'oncologie radiothérapie, Institut universitaire du cancer de Toulouse-Oncopole (IUCT-oncopole), université Paul-Sabatier Toulouse III, 1, avenue Irène-Joliot-Curie, 31059 Toulouse cedex 9, France.
| | - V Bernier
- Département d'oncologie radiothérapie, Institut de cancérologie de Lorraine centre Alexis-Vautrin, 6, avenue de Bourgogne, CS 30519, 54519 Vandœuvre-lès-Nancy cedex, France
| | - L Padovani
- Département de cancérologie radiothérapie, CHU, 13000 Marseille, France; Université Aix-Marseille, 13000 Marseille, France
| | - V Martin
- Département de cancérologie radiothérapie, institut Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France
| | - C Chargari
- Département d'oncologie radiothérapie, institut Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France; Service de santé des armées, 75000 Paris, France
| | - S Supiot
- Département de radiothérapie, Institut de cancérologie de l'Ouest (ICO) centre René-Gauducheau, 44800 Saint-Herblain, France; Université de Nantes, 44000 Nantes, France
| | - L Claude
- Département d'oncologie radiothérapie, centre Léon-Bérard, 28, rue Laennec, 69373 Lyon cedex 08, France
| |
Collapse
|
6
|
Martin V, Gregoire E, Chopinet S, Scatton O, Dubois R, Lasseur A, Dumortier J, Boillot O. Acquired diaphragmatic hernia after hepatectomy and liver transplantation in adults and children: A case series and literature review. Ann Hepatobiliary Pancreat Surg 2021; 25:462-471. [PMID: 34845117 PMCID: PMC8639310 DOI: 10.14701/ahbps.2021.25.4.462] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/14/2021] [Revised: 04/22/2021] [Accepted: 05/03/2021] [Indexed: 12/02/2022] Open
Abstract
Backgrounds/Aims Acquired diaphragmatic hernia is a rare complication following liver surgery in adult and pediatric patients. This study aims to describe main features occurring in adult and pediatric patients after liver surgery and report an up-date review of the literature. Methods All adult and pediatric patients who were diagnosed with postoperative acquired diaphragmatic hernia in Lyon and Marseille University Hospitals were included in this study. Diagnosis, clinical, radiologic, and therapeutic data were analysed retrospectively from medical papers and/or electronic records. Results Thirteen adults with a median age of 50 years (range, 30–67 years) and 5 children aged 2.4 years (range, 0.9–4 years) were diagnosed with acquired diaphragmatic hernia after a median time of 65.1 (range, 1.8–244.7) and 2 (range, 0.33–10.9) months, respectively, following surgeries (5 live-donor right hepatectomies, 5 right and 1 left hepatectomies for tumors and cysts, and 2 whole liver transplantations in adults; and 5 liver transplantations with left lateral section in children). Eleven patients presented digestive and/or thoracic symptoms whereas seven were asymptomatic and diagnosed by routine imaging follow-up. All patients were re-operated with a median delay of 2.4 months (range, 0–25.3 months) for adults and 1 day (range, 0–2 days) for children. Two recurrences resulted in a secondary surgical repair. Conclusions Acquired diaphragmatic hernia is a rare and potentially serious event after liver surgery. Recognition and surgical repair of this particular complication should be considered in the setting of unexplained abdominal and/or thoracic symptoms. Preventive measures should be taken intraoperatively.
Collapse
Affiliation(s)
- Valentine Martin
- Department of Digestive Diseases, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France
| | - Emilie Gregoire
- Department of General Surgery and Liver Transplantation, Aix-Marseille University, Assistance Publique des Hôpitaux de Marseille, la Timone Hospital, Marseille, France
| | - Sophie Chopinet
- Department of General Surgery and Liver Transplantation, Aix-Marseille University, Assistance Publique des Hôpitaux de Marseille, la Timone Hospital, Marseille, France
| | - Olivier Scatton
- Department of Hepato-Biliary and Pancreatic and Liver Transplantation, AP-HP Pitié-Salpetrière Hospital, Paris, France
| | - Rémi Dubois
- Department of Pediatric Surgery, Femme Mère Enfant Hospital, Hospices Civils de Lyon, Lyon, France
| | - Antoinette Lasseur
- Department of Digestive Diseases, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France
| | - Jérôme Dumortier
- Department of Digestive Diseases, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France.,Department of Medicine, University Claude Bernard Lyon 1, Lyon, France
| | - Olivier Boillot
- Department of Digestive Diseases, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France.,Department of General Surgery and Liver Transplantation, Aix-Marseille University, Assistance Publique des Hôpitaux de Marseille, la Timone Hospital, Marseille, France.,Department of Medicine, University Claude Bernard Lyon 1, Lyon, France
| |
Collapse
|
7
|
Abstract
Abstract
Study question
Could the urine estrone–3-glucuronide (E3G) assay be used efficiently to monitor a controlled ovarian hyperstimulation (COH) cycle, in comparison to a serum estradiol (E2) assay?
Summary answer
E3G testing provides an alternative to serum E2 assessment and a new “patient friendly” approach for COH monitoring.
What is known already
In many IVF clinics basic monitoring tools for controlled ovarian stimulation during IVF procedure are ultrasound measurements of follicle growth and hormone assessment of serum E2 levels. The monitoring can occur 4–6 times during stimulation, but repeated blood sampling causes patient stress. In contrast, E3G sampling, one of principal metabolites of estradiol in urine, is non-invasive and can be performed by the patients themselves and measured by fluorescent immunoassay. A correlation has been shown between concentrations of E2 present in plasma and concentrations of E3G in different phases of menstruation cycle.
Study design, size, duration
This is a pilot, prospective study, in a single IVF clinic. Twenty female participants were recruited November 2020 -January 2021, aged 25–43 years and BMI: 18–28kg/m2. Dynamic change of serum E2 and urine E3G at ovarian stimulation monitoring are being analyzed.
Participants/materials, setting, methods
Concurrent urine E3G and serum E2 values were collected from patients who provided between 2 and 4 samples on different days of their COH IVF cycle. Serum E2 values were assessed routinely, while E3G values were measured and validated using a fluorescent immunoassay Mira Fertility Plus® analyzer.Main results and the role of chance: The urine E3G of assay was validated for intra- and inter-assay variability with a coefficient of variation of < 20%. It was also validated for analytical and functional sensitivity and sample stability. Linear regression of serum E2 and E3G values of 56 early morning urine samples who had evaluated between Days 4 and 13 of menstruation cycle provided an R = 0,81. Urine E3G values also correlated to follicle growth. Patient survey results showed that urine sampling was the preferred method of analysis.
Limitations, reasons for caution
We have provided proof of principle that urine E3G measurement can be accurately carried out using fluorescent immunoassay technology during routine COH for IVF cycles. The patients’ study group has to be expanded in order to enable us to find the appropriate place of urine E3G assay in COH protocol.
Wider implications of the findings: Urine E3G testing correlates well to serum E2 assessment in COH. Urine E3G assay provides an alternative to serum-based assessment. The ease of urine sampling allows a reduction in patient discomfort during venopuncture, costs, time, and infection risks in epidemics/pandemics, like COViD–19, and offers a patient-friendly approach to ovarian stimulation.
Trial registration number
NA
Collapse
Affiliation(s)
- I Vladimirov
- SBALAGRM-SOFIA, IVF unit, Sofia, Bulgaria
- Sofia University “St. Kliment Ohridski”- Sofia- Bulgaria, Faculty of Biology, Sofia, Bulgaria
| | - V Martin
- SBALAGRM-SOFIA, IVF unit, Sofia, Bulgaria
| | - T Desislava
- SBALAGRM-SOFIA, IVF unit, Sofia, Bulgaria
- Sofia University “St. Kliment Ohridski”- Sofia- Bulgaria, Faculty of Biology, Sofia, Bulgaria
| |
Collapse
|
8
|
Di Perri D, Jouglar E, Blanc E, Ducassou A, Huchet A, Vigneron C, Escande A, Chapet S, Leseur J, Bernier V, Carrie C, Martin V, Claude L. Hypofractionated stereotactic body radiation therapy (SBRT) in pediatric patients: preliminary toxicity results of a national prospective multicenter study. Br J Radiol 2021; 94:20210176. [PMID: 34233469 DOI: 10.1259/bjr.20210176] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
OBJECTIVES While hypofractionated stereotactic body radiotherapy (SBRT) has been largely adopted in the adult setting, its use remains limited in pediatric patients. This is due, among other factors, to fear of potential toxicities of hypofractionated regimens at a young age. In this context, we report the preliminary acute (<3 months from SBRT) and middle-term (3-24 months) toxicity results of a national prospective study investigating SBRT in pediatric patients. METHODS Between 2013 and 2019, 61 patients were included. The first 40 patients (median age: 12 y, range: 3-20) who completed a 2-year-follow-up were included in the present analysis. SBRT was used for treating lung, brain or (para)spinal lesions, either as first irradiation (35%) or in the reirradiation setting (65%). RESULTS Acute and middle-term grade ≥2 toxicities occurred in 12.5 and 7.5% of the patients, respectively. No grade ≥4 toxicities occurred. Almost all toxicities occurred in the reirradiation setting. CONCLUSION SBRT showed a favorable safety profile in young patients treated for lung, brain, and (para)spinal lesions. ADVANCES IN KNOWLEDGE SBRT appeared to be safe in pediatric patients treated for multiple oncology indications. These results support further evaluation of SBRT, which may have a role to play in this patient population in the future.
Collapse
Affiliation(s)
- Dario Di Perri
- Department of radiation oncology, Centre Léon Bérard, Lyon, France
| | - Emmanuel Jouglar
- Department of radiation oncology, Institut de Cancérologie de l'Ouest, Nantes, France
| | - Ellen Blanc
- Department of clinical research and innovation, Centre Léon Bérard, Lyon, France
| | - Anne Ducassou
- Department of radiation oncology, Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France
| | - Aymeri Huchet
- Department of radiation oncology, Centre Hospitalier Universitaire, Bordeaux, France
| | - Céline Vigneron
- Department of radiation oncology, Centre Paul Strauss, Strasbourg, France
| | - Alexandre Escande
- Department of radiation oncology, Centre Oscar Lambret, Lille, France
| | - Sophie Chapet
- Department of radiation oncology, Centre Hospitalier Universitaire, Tours, France
| | - Julie Leseur
- Department of radiation oncology, Centre Eugène Marquis, Rennes, France
| | - Valérie Bernier
- Department of radiation oncology, Institut de Cancérologie de Lorraine, Nancy, France
| | - Christian Carrie
- Department of radiation oncology, Centre Léon Bérard, Lyon, France
| | - Valentine Martin
- Department of radiation oncology, Institut Gustave Roussy, Villejuif, France
| | - Line Claude
- Department of radiation oncology, Centre Léon Bérard, Lyon, France
| |
Collapse
|
9
|
Engstrand J, Abreu de Carvalho LF, Aghayan D, Balakrishnan A, Belli A, Björnsson B, Dasari BVM, Detry O, Di Martino M, Edwin B, Erdmann J, Fristedt R, Fusai G, Gimenez-Maurel T, Hemmingsson O, Hidalgo Salinas C, Isaksson B, Ivanecz A, Izzo F, Knoefel WT, Kron P, Lehwald-Tywuschik N, Lesurtel M, Lodge JPA, Machairas N, Marino MV, Martin V, Paterson A, Rystedt J, Sandström P, Serrablo A, Siriwardena AK, Taflin H, van Gulik TM, Yaqub S, Özden I, Ramia JM, Sturesson C. Liver resection and ablation for squamous cell carcinoma liver metastases. BJS Open 2021; 5:6356812. [PMID: 34426830 PMCID: PMC8382975 DOI: 10.1093/bjsopen/zrab060] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2021] [Accepted: 05/17/2021] [Indexed: 12/30/2022] Open
Abstract
Background Limited evidence exists to guide the management of patients with liver metastases from squamous cell carcinoma (SCC). The aim of this retrospective multicentre cohort study was to describe patterns of disease recurrence after liver resection/ablation for SCC liver metastases and factors associated with recurrence-free survival (RFS) and overall survival (OS). Method Members of the European–African Hepato-Pancreato-Biliary Association were invited to include all consecutive patients undergoing liver resection/ablation for SCC liver metastases between 2002 and 2019. Patient, tumour and perioperative characteristics were analysed with regard to RFS and OS. Results Among the 102 patients included from 24 European centres, 56 patients had anal cancer, and 46 patients had SCC from other origin. RFS in patients with anal cancer and non-anal cancer was 16 and 9 months, respectively (P = 0.134). A positive resection margin significantly influenced RFS for both anal cancer and non-anal cancer liver metastases (hazard ratio 6.82, 95 per cent c.i. 2.40 to 19.35, for the entire cohort). Median survival duration and 5-year OS rate among patients with anal cancer and non-anal cancer were 50 months and 45 per cent and 21 months and 25 per cent, respectively. For the entire cohort, only non-radical resection was associated with worse overall survival (hazard ratio 3.21, 95 per cent c.i. 1.24 to 8.30). Conclusion Liver resection/ablation of liver metastases from SCC can result in long-term survival. Survival was superior in treated patients with liver metastases from anal versus non-anal cancer. A negative resection margin is paramount for acceptable outcome.
Collapse
Affiliation(s)
- J Engstrand
- Division of Surgery, Department of Clinical Sciences, Karolinska Institutet at Danderyd Hospital, Stockholm, Sweden
| | - L F Abreu de Carvalho
- Department of Hepatopancreatobiliary Surgery and Liver Transplantation, Ghent University Hospital, Ghent, Belgium
| | - D Aghayan
- The Intervention Centre, Oslo University Hospital, Institute of Clinical Medicine, Medical Faculty, University of Oslo, Oslo, Norway.,Department of Surgery N1, Yerevan State Medical University after M. Heratsi, Yerevan, Armenia
| | - A Balakrishnan
- Department of Surgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - A Belli
- Department of Abdominal Oncology, HPB Surgical Oncology Unit, National Cancer Institute, Fondazione G. Pascale-IRCCS, Naples, Italy
| | - B Björnsson
- Department of Surgery in Linköping, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden
| | - B V M Dasari
- Department of Hepatobiliary and Pancreatic Surgery, Queen Elizabeth Hospital, Birmingham, UK
| | - O Detry
- Department of Abdominal Surgery and Transplantation, CHU Liège, Liège, Belgium
| | - M Di Martino
- HPB Unit, Department of General and Digestive Surgery, Hospital Universitario La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Universidad Autónoma de Madrid (UAM), Madrid, Spain
| | - B Edwin
- The Intervention Centre, Oslo University Hospital, Institute of Clinical Medicine, Medical Faculty, University of Oslo, Oslo, Norway
| | - J Erdmann
- Department of Surgery, Cancer Centre Amsterdam, Amsterdam UMC, University of Amsterdam, the Netherlands
| | - R Fristedt
- Department of Surgery, Skåne University Hospital, Lund University, Lund, Sweden
| | - G Fusai
- Department of HPB and Liver Transplant Surgery, Royal Free Hospital, NHS Foundation Trust, London, UK
| | - T Gimenez-Maurel
- Department of Surgery, Miguel Servet University Hospital, Zaragoza, Spain
| | - O Hemmingsson
- Department of Surgical and Perioperative Sciences, Umeå University, Umeå, Sweden
| | - C Hidalgo Salinas
- Department of HPB and Liver Transplant Surgery, Royal Free Hospital, NHS Foundation Trust, London, UK
| | - B Isaksson
- Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
| | - A Ivanecz
- Department of Abdominal and General Surgery, University Medical Centre Maribor, Maribor, Slovenia
| | - F Izzo
- Department of Abdominal Oncology, HPB Surgical Oncology Unit, National Cancer Institute, Fondazione G. Pascale-IRCCS, Naples, Italy
| | - W T Knoefel
- Department of Surgery (A), Heinrich-Heine-University and University Hospital Düsseldorf, Düsseldorf, Germany
| | - P Kron
- Department of Hepatobiliary Surgery, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - N Lehwald-Tywuschik
- Department of Surgery (A), Heinrich-Heine-University and University Hospital Düsseldorf, Düsseldorf, Germany
| | - M Lesurtel
- Department of Digestive Surgery and Liver Transplantation, Croix-Rousse University Hospital, Hospices Civils de Lyon, University of Lyon I, Lyon, France
| | - J P A Lodge
- Department of Hepatobiliary Surgery, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - N Machairas
- 3rd Department of Surgery, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece
| | - M V Marino
- General Surgery Department, Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello, Palermo (PA), Abano, Italy.,General Surgery Department, Policlinico Abano Terme, Abano, Italy
| | - V Martin
- Department of Digestive Surgery and Liver Transplantation, Croix-Rousse University Hospital, Hospices Civils de Lyon, University of Lyon I, Lyon, France
| | - A Paterson
- Department of Surgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - J Rystedt
- Department of Surgery, Skåne University Hospital, Lund University, Lund, Sweden
| | - P Sandström
- Department of Surgery in Linköping, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden
| | - A Serrablo
- Department of Surgery, Miguel Servet University Hospital, Zaragoza, Spain
| | - A K Siriwardena
- Hepatobiliary Surgery Unit, Manchester Royal Infirmary, Manchester, UK
| | - H Taflin
- Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Sweden
| | - T M van Gulik
- Department of Surgery, Cancer Centre Amsterdam, Amsterdam UMC, University of Amsterdam, the Netherlands
| | - S Yaqub
- Department of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Oslo, Norway
| | - I Özden
- Department of General Surgery, Istanbul University School of Medicine, Istanbul, Turkey
| | - J M Ramia
- Hospital General Universitario de Alicante. ISABIAL Alicante, Spain
| | - C Sturesson
- Division of Surgery, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
| | | |
Collapse
|
10
|
Medrano M, Soleto A, Pastor C, Rodríguez C, Carrasco R, Lapayese F, de la Peña A, Pereira A, Rincón E, Cabrera S, Ramos F, de la Cal E, Mota F, Queral V, Lopez-Heredero R, Manzanares A, Alén-Cordero C, Letellier L, Vives S, Martin V, Guern FL, Piqueras J, Kocan M. Design overview of ex-vessel components for the Wide Angle Viewing System diagnostic for ITER Equatorial Port 12. Fusion Engineering and Design 2021. [DOI: 10.1016/j.fusengdes.2021.112651] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
11
|
Bompas E, Martin V, Meniai F, Toulmonde M, Marec-Berard P, Claude L, Ducimetiere F, Chargari C, Minard-Colin V, Corradini N, Laurence V, Piperno-Neumann S, Defachelles AS, Bernier V, Italiano A, Orbach D, Blay JY, Gaspar N, Berlanga P. Management of sarcomas in children, adolescents and adults: Interactions in two different age groups under the umbrellas of GSF-GETO and SFCE, with the support of the NETSARC+ network. Bull Cancer 2021; 108:163-176. [PMID: 33455736 DOI: 10.1016/j.bulcan.2020.10.009] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2020] [Revised: 10/17/2020] [Accepted: 10/27/2020] [Indexed: 11/17/2022]
Abstract
Sarcomas are a rare heterogeneous group of malignant neoplasms that can arise in almost any anatomic site and any age. Close collaboration among adult and pediatric cancer specialists in the management of these tumors is of foremost importance. In this review, we present the current multidisciplinary organization in care of patients with sarcoma in France and we review the main advances made in the last decades in systemic and radiotherapy treatment in the main sarcoma types diagnosed in children, adolescents and young adults (AYA), thanks to the international collaboration.
Collapse
Affiliation(s)
- Emmanuelle Bompas
- Centre René Gauducheau, Medical Oncology Department, Saint-Herblain, France
| | - Valentine Martin
- Department of Radiation Oncology, Gustave Roussy, Villejuif, France
| | - Fatima Meniai
- University Lille, Inserm, U1189 - ONCO-THAI - Assisted Laser Therapy and Immunotherapy for Oncology, 59000 Lille, France
| | - Maud Toulmonde
- Institut Bergonié, Medical Oncology Department, Bordeaux, France
| | | | - Line Claude
- Centre Léon Bérard, Department of radiotherapy, Lyon, France
| | | | - Cyrus Chargari
- Department of Radiation Oncology, Gustave Roussy, Villejuif, France
| | | | - Nadège Corradini
- Centre Léon Bérard, Department of Pediatric Oncology, Lyon, France
| | | | | | | | - Valérie Bernier
- Oncology Radiotherapy Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France
| | | | - Daniel Orbach
- Department of Pediatric Oncology, Institut Curie, Paris, France
| | - Jean-Yves Blay
- Medical Oncology Department, Centre Léon-Bérard, Lyon, France
| | - Nathalie Gaspar
- Department of Pediatric and Adolescent Oncology, Gustave Roussy, Villejuif, France
| | - Pablo Berlanga
- Department of Pediatric and Adolescent Oncology, Gustave Roussy, Villejuif, France.
| |
Collapse
|
12
|
Romano E, Simon R, Minard-Colin V, Martin V, Bockel S, Espenel S, Fresneau B, Metayer L, Levy A, Guerin F, Martelli H, Dumas I, Bolle S, Deutsch E, Haie-Meder C, Chargari C. Analysis of Radiation Dose/Volume Effect Relationship for Anorectal Morbidity in Children Treated for Pelvic Malignancies. Int J Radiat Oncol Biol Phys 2021; 109:231-241. [PMID: 32805302 DOI: 10.1016/j.ijrobp.2020.08.033] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2020] [Revised: 08/07/2020] [Accepted: 08/10/2020] [Indexed: 01/14/2023]
Abstract
PURPOSE To examine dose-volume effect relationships for anorectal morbidity in children treated with image-guided brachytherapy for pelvic tumors. METHODS AND MATERIALS Medical records of all consecutive children with pelvic tumors treated in our center and receiving image-guided pulsed-dose-rate brachytherapy with or without external beam radiation therapy (EBRT) between 2005 and 2019 were reviewed. The effect of the minimal doses to the most exposed 0.5 cm3, 1 cm3, and 2 cm3 of the anorectum (respectively: D0.5cm3, D1cm3, and D2cm3), total reference air kerma (TRAK), and volume of 100% isodose was examined for anorectal toxicities. RESULTS Seventy-eight consecutive children were included. Median age was 2.9 years (range, 0.8-14.9 years). Most of the tumors were bladder or prostate (67%) or vaginal (22%) rhabdomyosarcoma. Six patients received EBRT in addition to brachytherapy. Median follow-up was 21.3 months. At last follow-up, 30 children (38%) had experienced Common Terminology Criteria for Adverse Events version 5 grade ≥1 acute or late anorectal events: 24% had grade 1 events, 7.7% had grade 2 events, and 6.4% had grade 3 events. No toxicity greater than grade 3 was observed (eg, fistula or stricture). In univariate analysis, the D0.5cm3 and D1cm3 were significant for probability of grade 1 to 3 (P = .009 and P = .017, respectively) and grade 2 to 3 anorectal morbidity (P = .007 and P = .049, respectively). There was no significant correlation for D2cm3 (P = .057 for grade 1-3; P = .407 for grade 2-3). A 10% probability (95% confidence interval, 4%-20%) for anorectal toxicity of grade 2 or greater was reached for a D0.5cm3 = 52 Gy. The age, EBRT use, TRAK, and treated volume values were not significant. CONCLUSIONS To our knowledge, this study is the first to show a significant dose-volume effect relationships for anorectal morbidity in children undergoing treatment with brachytherapy. Integrating these data into brachytherapy treatment planning could help to optimize the therapeutic index in these young patients.
Collapse
Affiliation(s)
- Edouard Romano
- Department of Radiation Oncology, Gustave Roussy Cancer Campus, Cancer Center, University Paris Saclay Medical Faculty, Villejuif, France
| | - Raphaël Simon
- Hospices Civils de Lyon, Lyon Est University Medical Faculty, Lyon, France
| | - Véronique Minard-Colin
- Department of Pediatric and Adolescent Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Valentine Martin
- Department of Radiation Oncology, Gustave Roussy Cancer Campus, Cancer Center, University Paris Saclay Medical Faculty, Villejuif, France
| | - Sophie Bockel
- Department of Radiation Oncology, Gustave Roussy Cancer Campus, Cancer Center, University Paris Saclay Medical Faculty, Villejuif, France
| | - Sophie Espenel
- Department of Radiation Oncology, Gustave Roussy Cancer Campus, Cancer Center, University Paris Saclay Medical Faculty, Villejuif, France
| | - Brice Fresneau
- Department of Pediatric and Adolescent Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Lucy Metayer
- Department of Pediatric and Adolescent Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Antonin Levy
- Department of Radiation Oncology, Gustave Roussy Cancer Campus, Cancer Center, University Paris Saclay Medical Faculty, Villejuif, France; INSERM 1030 Molecular radiotherapy, Gustave Roussy Cancer Campus, Villejuif, France
| | - Florent Guerin
- Department of Pediatric Surgery, Kremlin Bicetre University Hospital, Kremlin Bicêtre, France
| | - Hélène Martelli
- Department of Pediatric Surgery, Kremlin Bicetre University Hospital, Kremlin Bicêtre, France
| | - Isabelle Dumas
- Department of Radiation Oncology, Gustave Roussy Cancer Campus, Cancer Center, University Paris Saclay Medical Faculty, Villejuif, France
| | - Stéphanie Bolle
- Department of Radiation Oncology, Gustave Roussy Cancer Campus, Cancer Center, University Paris Saclay Medical Faculty, Villejuif, France
| | - Eric Deutsch
- Department of Radiation Oncology, Gustave Roussy Cancer Campus, Cancer Center, University Paris Saclay Medical Faculty, Villejuif, France; INSERM 1030 Molecular radiotherapy, Gustave Roussy Cancer Campus, Villejuif, France
| | - Christine Haie-Meder
- Department of Radiation Oncology, Gustave Roussy Cancer Campus, Cancer Center, University Paris Saclay Medical Faculty, Villejuif, France
| | - Cyrus Chargari
- Department of Radiation Oncology, Gustave Roussy Cancer Campus, Cancer Center, University Paris Saclay Medical Faculty, Villejuif, France; INSERM 1030 Molecular radiotherapy, Gustave Roussy Cancer Campus, Villejuif, France; French Military Health Academy, Ecole du Val-de-Grâce, Paris, France; Institut de Recherche Biomédicale des Armées, Brétigny sur Orge, France.
| |
Collapse
|
13
|
Romano E, Simon R, Martin V, Bolle S, Andraud M, Boulle G, Kissel M, Kumar T, Martelli H, Guerin F, Deutsch E, Haie-Meder C, Chargari C. OC-1045: Dose-volume effect relationships for rectal morbidity after brachytherapy for pediatric cancers. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01982-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
14
|
Jouglar E, Escande A, Martin V, Demoor-Goldschmidt C, Carrie C, Claude L, Bernier-Chastagner V. [Influence of age on indications and modalities of radiation therapy: What to keep in mind for adolescents and young adults?]. Bull Cancer 2020; 108:203-209. [PMID: 33051053 DOI: 10.1016/j.bulcan.2020.09.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2020] [Revised: 08/25/2020] [Accepted: 09/06/2020] [Indexed: 10/23/2022]
Abstract
When using radiation therapy for adolescents and young adults (AYA), paediatricians, adults' oncologists and radiation oncologists need to keep in mind several particularities through the whole therapeutic process. They embrace the indication, target volumes, prescribed dose, treatment techniques and follow-up. Indeed, the young age and the cancer features that characterised this population influence the modalities of irradiation. This article highlights the key points of AYA care with radiation therapy.
Collapse
Affiliation(s)
- Emmanuel Jouglar
- Institut de cancérologie de l'ouest, service de radiothérapie, boulevard Jacques-Monod, 44800 Saint-Herblain, France.
| | - Alexandre Escande
- Centre Oscar-Lambret, département universitaire de radiothérapie, 59800 Lille, France; Université de Lille 3, faculté Henri-Warembourg, Laboratoire cristal UMR 9189, 59800 Lille, France
| | - Valentine Martin
- Gustave-Roussy, département universitaire de radiothérapie, 94800 Villejuif, France
| | - Charlotte Demoor-Goldschmidt
- Université Paris-Saclay, Université Paris-Sud, UVSQ, cancer et radiothérapie, Inserm U1018, 94800 Villejuif, France
| | - Christian Carrie
- Centre Léon-Berard, département de radiothérapie, 69008 Lyon, France
| | - Line Claude
- Centre Léon-Berard, département de radiothérapie, 69008 Lyon, France
| | - Valérie Bernier-Chastagner
- Institut de cancérologie de Lorraine, département de radiothérapie, 3, avenue de Bourgogne, 54500 Vandoeuvre-lès-Nancy, France
| |
Collapse
|
15
|
Saleh K, Michot JM, Schernberg A, Lazarovici J, Chahine C, Danu A, Khalife-Saleh N, Rossignol J, Ghez D, Martin V, Mazeron R, Fermé C, Boros A, Ribrag V, Girinsky T. Repeated courses of low-dose 2 × 2 Gy radiation therapy in patients with indolent B-cell non-Hodgkin lymphomas. Cancer Med 2020; 9:3725-3732. [PMID: 32249547 PMCID: PMC7286454 DOI: 10.1002/cam4.2796] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2019] [Revised: 11/09/2019] [Accepted: 12/06/2019] [Indexed: 11/12/2022] Open
Abstract
Purpose In patients with indolent B‐cell non‐Hodgkin's lymphoma (B‐NHL), one course of low‐dose radiotherapy (LD‐RT) 2 × 2 Gy is emerging as new option of therapy in palliative setting. Efficacy of LD‐RT when repeated remains to be determinate. This study aims to assess the efficacy of repeated LD‐RT given in patients with indolent B‐NHL. Materials and Methods All consecutive adult patients who received two or more courses of LD‐RT 2 × 2 Gy for indolent B‐NHL at Gustave Roussy institution, during the period 1990‐2015 were retrospectively investigated. Results Thirty‐three patients received two or more courses of LD‐RT for indolent B‐NHL during the study period. The median age was 57 (range 37‐80) years, histological types were distributed among follicular lymphoma (n = 24 pts; 73%), marginal‐zone lymphoma (n = 6 pts; 18%), and primary cutaneous follicle center lymphoma (n = 3 pts; 9%). The median number of low‐dose radiation therapy courses given per patients was 2 (range 2‐6). The overall response rates following the first and the second course of LD‐RT were 96% and 88%, respectively (P = .31). The 1‐ and 2‐years local control rates following the first courses of LD‐RT were 94% (CI 95: 86‐100) and 94% (CI 95: 86‐98); and were 91% (CI 95: 82‐100) and 88% (CI 95: 77‐100) following the second course of LD‐RT (P = .39). Conclusion The repeated courses of LD‐RT offered similar efficacy compare with the first course in patients with indolent B‐NHL. LD‐RT repeated is a simple, easy to give, and non‐toxic asset that could be investigated as treatment option in patients with indolent B‐NHL.
Collapse
Affiliation(s)
- Khalil Saleh
- Department of Hematology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Jean-Marie Michot
- Department of Hematology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.,Drug Development Department, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Antoine Schernberg
- Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Julien Lazarovici
- Department of Hematology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Claude Chahine
- Department of Hematology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Alina Danu
- Department of Hematology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Nadine Khalife-Saleh
- Department of Hematology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Julien Rossignol
- Department of Hematology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - David Ghez
- Department of Hematology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Valentine Martin
- Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Renaud Mazeron
- Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Christophe Fermé
- Department of Hematology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Angela Boros
- Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Vincent Ribrag
- Department of Hematology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.,Drug Development Department, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Theodore Girinsky
- Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| |
Collapse
|
16
|
Bordet F, Inthavong D, Fremy JM, Aspe D, Durand T, Ducher M, Fontayne N, Grignon E, Herbreteau C, Hulot S, Le Bigot C, Marengue E, Martin V, Ranneaud S, Sartre L, Vouillon B. Interlaboratory Study of a Multiresidue Gas Chromatographic Method for Determination of Organochlorine and Pyrethroid Pesticides and Polychlorobiphenyls in Milk, Fish, Eggs, and Beef Fat. J AOAC Int 2019. [DOI: 10.1093/jaoac/85.6.1398] [Citation(s) in RCA: 45] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Abstract
An interlaboratory study was conducted to validate a gas chromatographic (GC) method for determination of 21 organochlorine pesticides, 6 pyrethroid pesticides, and 7 polychlorobiphenyl (PCB) congeners in milk, beef fat, fish, and eggs. The method was performed at low contamination levels, which represent relevant contents in food, and is an extension of the European standard (method NF-EN-1528, Parts 1–4). It enlarges the applicable scope of the reference EN method to pyrethroid pesticides and proposes the use of solid-phase extraction (SPE) as a cleanup procedure. Cryogenic extraction was made, and SPE cleanup was performed with 2 successive SPE cartridges: C18 and Florisil®. After injection of the purified extract onto a GC column, residues were measured by electron capture detection. Food samples (liquid milk, beef fat, mixed fish, and mixed eggs) were prepared, tested for homogeneity, and sent to 17 laboratories in France. Test portions were spiked with 27 pesticides and 7 PCBs at levels from 26 to 45, 4 to 27, 31 to 67, and 19 to 127 ng/g into milk, eggs, fish, and fat, respectively. Based on results for spiked samples, the relative standard deviation for repeatability ranged from 1.5 to 6.8% in milk, 3 to 39% in eggs, 4.5 to 12.2% in fish, and 7 to 13% in fat. The relative standard deviation for reproducibility ranged from 33 to 50% in milk, 29 to 59% in eggs, 31 to 57% in fish, and 30 to 62% in fat. This method showed acceptable intra- and interlaboratory precision data, as corroborated by HORRAT values at low levels of pesticide and PCB contamination. The statistical evaluation of the results was performed according to the International Organization for Standardization (ISO; ISO 3534 standard) and 5725-2 Guideline.
Collapse
Affiliation(s)
- François Bordet
- Agence Française de Sécurité Sanitaire des Aliments, Unité Contaminants de l'Environnement, 10 Rue Pierre Curie, 94704, Maisons-Alfort, Paris, France
| | - Dary Inthavong
- Agence Française de Sécurité Sanitaire des Aliments, Unité Contaminants de l'Environnement, 10 Rue Pierre Curie, 94704, Maisons-Alfort, Paris, France
| | - Jean-Marc Fremy
- Agence Française de Sécurité Sanitaire des Aliments, Unité Contaminants de l'Environnement, 10 Rue Pierre Curie, 94704, Maisons-Alfort, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Martin V, Esquembri S, Awanzino C, Nieto J, Ruiz M, Reichle R. ITER upper visible/infrared wide angle viewing system: I&C design and prototyping status. Fusion Engineering and Design 2019. [DOI: 10.1016/j.fusengdes.2019.04.015] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
18
|
Aleman B, Ricardi U, van der Maazen R, Meijnders P, Beijert M, Boros A, Izar F, Janus C, Levis M, Martin V, Specht L, Corning C, Clementel E, Fortpied C, Raemaekers J, Andre M, Federico M, Girinsky T. PRELIMINARY RESULTS OF A QUALITY CONTROL STUDY ON INVOLVED NODE RADIOTHERAPY IN THE EORTC/LYSA/FIL H10 TRIAL ON STAGES I/II HODGKIN LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.166_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- B.M. Aleman
- Radiation Oncology; The Netherlands Cancer Institute; Amsterdam Netherlands
| | - U. Ricardi
- Oncology; University of Turin; Turin Italy
| | | | - P. Meijnders
- Radiotherapy; GZA Ziekenhuizen campus Sint-Augustinus; Wilrijk Belgium
| | - M. Beijert
- Radiotherapy; University Medical Center Groningen; Groningen Netherlands
| | - A. Boros
- Radiotherapy; Institut Gustave Roussy; Villejuif France
| | - F. Izar
- Radiotherapy; Institut universitaire du cancer de Toulouse; Toulouse France
| | - C.P. Janus
- Radiotherapy; Erasmus MC Cancer Institute; Rotterdam Netherlands
| | - M. Levis
- Oncology; University of Turin; Turin Italy
| | - V. Martin
- Radiotherapy; Institut Gustave Roussy; Villejuif France
| | - L. Specht
- Oncology; Rigshospitalet; Copenhagen Denmark
| | - C. Corning
- Head Quarters; European Organisation for Research and Treatment of Cancer; Brussels Belgium
| | - E. Clementel
- Head Quarters; European Organisation for Research and Treatment of Cancer; Brussels Belgium
| | - C. Fortpied
- Head Quarters; European Organisation for Research and Treatment of Cancer; Brussels Belgium
| | | | - M.P. Andre
- Hematology; CHU UCL Mont-Godinne-Dinant; Yvoir Belgium
| | - M. Federico
- Oncology; University of Modena and Reggio Emilia; Modena Italy
| | - T. Girinsky
- Radiotherapy; Institut Gustave Roussy; Villejuif France
| |
Collapse
|
19
|
Martin V, Fariña L, Medina K, Boido E, Dellacassa E, Mas A, Carrau F. Oenological attributes of the yeast Hanseniaspora vineaeand its application for white and red winemaking. BIO Web Conf 2019. [DOI: 10.1051/bioconf/20191202010] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Flavour and some compounds associated with wine colour are known to be yeast strain-dependent. These metabolites are important for the sensory quality of wines, studies searching for increase aroma and color are a key area today in winemaking. The aim of this work was to study the oenological potential of the two main strains of Hanseniaspora vineae,native to Uruguay to better understand their successful application at winery level. It is known that these strains contribute with extracellular proteases and β-glucosidase enzyme activities that might increase cell lysis and flavor depending in grape varieties. Application and nutrient management of the process of these strains in production of white wines (Chardonnay, Macabeo and Petit Manseng) and red wine Tannat are discussed. Wines were evaluated to determine the volatile compounds composition and their effect compared to conventional processes. Low production of short and medium chain fatty acids and ethyl esters, and high production of acetate esters and isoprenoids are found compared to S. cerevisiaestrains. The most outstanding characteristic of the species H. vineaewas the production of benzenoids, phenylpropanoids and acetate esters. This behavior was reflected in the sensory evaluation, where all the fermentations performed with H. vineaewere considered superior compared to Saccharomyces cerevisiaewine strains.
Collapse
|
20
|
Quéro L, Gilardin L, Fumagalli I, Martin V, Guillerm S, Bauduceau O, Kirova YM, Hennequin C, Brice P. Anti-PD-1 immunotherapy in combination with sequential involved-site radiotherapy in heavily pretreated refractory Hodgkin lymphoma. Cancer Radiother 2019; 23:132-137. [PMID: 30733172 DOI: 10.1016/j.canrad.2018.05.002] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2018] [Accepted: 05/03/2018] [Indexed: 11/24/2022]
Abstract
The purpose of this study was to assess efficacy and tolerance of anti-programmed death (PD)-1 immunotherapy in combination with sequential involved-site radiotherapy in heavily pretreated refractory Hodgkin lymphoma. In this case series, we reported the outcome of four heavily pretreated patients with refractory Hodgkin lymphoma treated by anti-PD-1 immunotherapy and involved site radiation therapy. After a median follow-up of 13-month, all patients were alive with complete metabolic response. After radiotherapy, all four patients experienced lung toxicity, which was resolved after antibiotherapy with or without corticosteroid treatment. Anti-PD-1 immunotherapy followed by involved-site radiotherapy is feasible and showed very encouraging results in heavily pretreated patients.
Collapse
Affiliation(s)
- L Quéro
- Radiation oncology department, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France.
| | - L Gilardin
- Department of haemato-oncology, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - I Fumagalli
- Radiation oncology department, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - V Martin
- Radiation oncology department, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - S Guillerm
- Radiation oncology department, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - O Bauduceau
- Radiation oncology department, Hartmann Oncology Radiotherapy Group, 4, rue Kléber, CS 90004, 92309 Levallois-Perret cedex, France
| | - Y M Kirova
- Radiation oncology department, institut Curie, 25, rue d'Ulm, 75005 Paris, France
| | - C Hennequin
- Radiation oncology department, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - P Brice
- Department of haemato-oncology, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France
| |
Collapse
|
21
|
Parchment B, Harrison J, McConnel C, Chiapetta H, Dearmin L, Beksinski C, Neveux A, Martin V, Block E, Adams-Progar A. PSV-10 Effect of feeding a yeast supplement to transition Holstein cows on colostrum quality and calf well-being. J Anim Sci 2018. [DOI: 10.1093/jas/sky404.100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- B Parchment
- Washington State University, Department of Animal Sciences,Pullman, WA, United States
| | - J Harrison
- Washington State University, Department of Animal Sciences,Pullman, WA, United States
| | - C McConnel
- Washington State University, Veterinary Clinical Sciences,Pullman, WA, United States
| | - H Chiapetta
- Washington State University, Department of Animal Sciences,Pullman, WA, United States
| | - L Dearmin
- Washington State University, Department of Animal Sciences,Pullman, WA, United States
| | - C Beksinski
- Washington State University, Department of Animal Sciences,Pullman, WA, United States
| | - A Neveux
- Washington State University, Department of Animal Sciences,Pullman, WA, United States
| | - V Martin
- Washington State University, Department of Animal Sciences,Pullman, WA, United States
| | - E Block
- Church and Dwight Animal Nutrition,Princeton, NJ, United States
| | - A Adams-Progar
- Washington State University, Department of Animal Sciences,Pullman, WA, United States
| |
Collapse
|
22
|
Guilhen M, Hennequin C, Ouzaid I, Fumagalli I, Martin V, Guillerm S, Mongiat-Artus P, Ravery V, Desgrandchamps F, Quéro L. Urinary function and quality of life after radiotherapy for prostate cancer in patients with prior history of surgical treatment for benign prostatic hyperplasia. Radiat Oncol 2018; 13:209. [PMID: 30355359 PMCID: PMC6201567 DOI: 10.1186/s13014-018-1149-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2018] [Accepted: 10/03/2018] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND To evaluate long-term IPSS score and urinary quality of life after radiotherapy for prostate cancer, in patients with prior history of surgical treatment for benign prostatic hyperplasia (BPH). METHODS In this retrospective study, we reviewed medical records of patients treated in our department, between 2007 and 2013 with surgery for BPH followed by radiotherapy for localized prostate cancer. Patients were contacted to fill in IPSS questionnaire and they were also asked for urinary quality of life. Predictive factors known to be associated with bad urinary function were also analysed. RESULTS Fifty-nine patients were included in our study. Median age was 70 years. Median follow-up was 4.6 years. Median radiotherapy dose was 78 Gy (5 × 2 Gy/week). Thirty patients (48.5%) received hormone therapy in combination with RT. Main surgery indications were urinary symptoms (65%) and urinary retention (20%). Five-year biochemical-disease free survival was 75% and 5-year clinical relapse free survival was 84%. At the time of the study, the IPSS after radiotherapy was as follows: 0-7: 77.6%; 8-19:20.7%; 20-35: 1.7%. Urinary quality of life was satisfactory for 74.2% of patients. After multivariate analysis, a high dose of RT and a medical history of hypertension were associated with a poorer quality of urinary life (p = 0.04). CONCLUSION External radiotherapy remains an appropriate treatment option without a major risk for deterioration in urinary function in patient with antecedent surgery for BPH. High dose of RT and a medical history of hypertension were associated with a poorer quality of urinary life.
Collapse
Affiliation(s)
- Mélanie Guilhen
- Radiation Oncology Department, Saint Louis Hospital, 1, avenue Claude Vellefaux, 75010, Paris, France
| | - Christophe Hennequin
- Radiation Oncology Department, Saint Louis Hospital, 1, avenue Claude Vellefaux, 75010, Paris, France
| | - Idir Ouzaid
- Radiation Oncology Department, Saint Louis Hospital, 1, avenue Claude Vellefaux, 75010, Paris, France
| | - Ingrid Fumagalli
- Radiation Oncology Department, Saint Louis Hospital, 1, avenue Claude Vellefaux, 75010, Paris, France
| | - Valentine Martin
- Radiation Oncology Department, Saint Louis Hospital, 1, avenue Claude Vellefaux, 75010, Paris, France
| | - Sophie Guillerm
- Radiation Oncology Department, Saint Louis Hospital, 1, avenue Claude Vellefaux, 75010, Paris, France
| | - Pierre Mongiat-Artus
- Radiation Oncology Department, Saint Louis Hospital, 1, avenue Claude Vellefaux, 75010, Paris, France
| | - Vincent Ravery
- Radiation Oncology Department, Saint Louis Hospital, 1, avenue Claude Vellefaux, 75010, Paris, France
| | - François Desgrandchamps
- Radiation Oncology Department, Saint Louis Hospital, 1, avenue Claude Vellefaux, 75010, Paris, France
| | - Laurent Quéro
- Radiation Oncology Department, Saint Louis Hospital, 1, avenue Claude Vellefaux, 75010, Paris, France.
| |
Collapse
|
23
|
Bibault JE, Denis F, Roué A, Gibon D, Fumagalli I, Hennequin C, Barillot I, Quéro L, Paumier A, Mahé MA, Servagi Vernat S, Créhange G, Lapeyre M, Blanchard P, Pointreau Y, Lafond C, Huguet F, Mornex F, Latorzeff I, de Crevoisier R, Martin V, Kreps S, Durdux C, Antoni D, Noël G, Giraud P. [Siriade 2.0: An e-learning platform for radiation oncology contouring]. Cancer Radiother 2018; 22:773-777. [PMID: 30360973 DOI: 10.1016/j.canrad.2018.02.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2017] [Revised: 01/23/2018] [Accepted: 02/08/2018] [Indexed: 12/26/2022]
Abstract
PURPOSE In 2008, the French national society of radiation oncology (SFRO) and the association for radiation oncology continued education (AFCOR) created Siriade, an e-learning website dedicated to contouring. MATERIAL AND METHODS Between 2015 and 2017, this platform was updated using the latest digital online tools available. Two main sections were needed: a theoretical part and another section of online workshops. RESULTS Teaching courses are available as online commented videos, available on demand. The practical section of the website is an online contouring workshop that automatically generates a report quantifying the quality of the user's delineation compared with the experts'. CONCLUSION Siriade 2.0 is an innovating digital tool for radiation oncology initial and continuous education.
Collapse
Affiliation(s)
- J-E Bibault
- Service d'oncologie radiothérapie, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; Université Paris Descartes, Paris Sorbonne Cité, 20, rue Leblanc, 75015 Paris, France
| | - F Denis
- Service de radiothérapie, centre Jean-Bernard, 9, rue Beauverger, 72000 Le Mans, France
| | - A Roué
- Institut national des sciences et techniques nucléaires, centre CEA de Saclay, D36, 91191 Gif-sur-Yvette, France
| | - D Gibon
- Aquilab, parc Eurasanté, biocentre Fleming, 250, rue Salvador-Allende, 59120 Loos, France
| | - I Fumagalli
- Service d'oncologie radiothérapie, hôpital Saint-Louis, 1, avenue Claude-Vellefau, 75010 Paris, France
| | - C Hennequin
- Service d'oncologie radiothérapie, hôpital Saint-Louis, 1, avenue Claude-Vellefau, 75010 Paris, France
| | - I Barillot
- Service d'oncologie radiothérapie, centre universitaire de cancérologie Henry-S.-Kaplan, 2, boulevard Tonnellé, 37044 Tours, France; Université François-Rabelais, 2, boulevard Tonnellé, 37044 Tours, France
| | - L Quéro
- Service d'oncologie radiothérapie, hôpital Saint-Louis, 1, avenue Claude-Vellefau, 75010 Paris, France
| | - A Paumier
- Service d'oncologie radiothérapie, institut de cancérologie de l'Ouest René-Gauducheau, boulevard Professeur-Jacques-Monod, 44805 Saint-Herblain, France
| | - M-A Mahé
- Service d'oncologie radiothérapie, institut de cancérologie de l'Ouest René-Gauducheau, boulevard Professeur-Jacques-Monod, 44805 Saint-Herblain, France
| | - S Servagi Vernat
- Service d'oncologie radiothérapie, institut Jean-Godinot, 1, rue Koenig, 51100 Reims, France
| | - G Créhange
- Service d'oncologie radiothérapie, centre Georges-François-Leclerc, 1, rue du Professeur-Marion, 21000 Dijon, France
| | - M Lapeyre
- Service d'oncologie radiothérapie, centre Jean-Perrin, 58, rue Montalembert, 63011 Clermont-Ferrand, France
| | - P Blanchard
- Service d'oncologie radiothérapie Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif, France
| | - Y Pointreau
- Service de radiothérapie, centre Jean-Bernard, 9, rue Beauverger, 72000 Le Mans, France
| | - C Lafond
- Service de radiothérapie, centre Jean-Bernard, 9, rue Beauverger, 72000 Le Mans, France
| | - F Huguet
- Service d'oncologie radiothérapie, hôpital Tenon, Hôpitaux universitaires de l'Est parisien, 4, rue de la Chine, 75020 Paris, France; Université Pierre-et-Marie-Curie, 4, rue de la Chine, 75020 Paris, France
| | - F Mornex
- Service d'oncologie radiothérapie, CHU Lyon Sud, 65, chemin du Grand-Revoyet, 69495 Pierre-Bénite, France
| | - I Latorzeff
- Service d'oncologie radiothérapie, clinique Pasteur, 1, rue de la Petite-Vitesse, 31300 Toulouse, France
| | - R de Crevoisier
- Service d'oncologie radiothérapie, centre Eugène-Marquis, avenue de la Bataille-Flandre-Dunkerque, 35700 Rennes, France
| | - V Martin
- Service d'oncologie radiothérapie, hôpital Saint-Louis, 1, avenue Claude-Vellefau, 75010 Paris, France
| | - S Kreps
- Service d'oncologie radiothérapie, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; Université Paris Descartes, Paris Sorbonne Cité, 20, rue Leblanc, 75015 Paris, France
| | - C Durdux
- Service d'oncologie radiothérapie, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; Université Paris Descartes, Paris Sorbonne Cité, 20, rue Leblanc, 75015 Paris, France
| | - D Antoni
- Département universitaire de radiothérapie, centre Paul-Strauss, 3, rue de la Porte-de-l'Hôpital, 67065 Strasbourg, France
| | - G Noël
- Département universitaire de radiothérapie, centre Paul-Strauss, 3, rue de la Porte-de-l'Hôpital, 67065 Strasbourg, France
| | - P Giraud
- Service d'oncologie radiothérapie, hôpital européen Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France; Université Paris Descartes, Paris Sorbonne Cité, 20, rue Leblanc, 75015 Paris, France.
| |
Collapse
|
24
|
Faivre JC, Bibault JE, Bellesoeur A, Salleron J, Wack M, Biau J, Cervellera M, Janoray G, Leroy T, Lescut N, Martin V, Molina S, Pichon B, Teyssier C, Thureau S, Mazeron JJ, Roché H, Culine S. Choosing a career in oncology: results of a nationwide cross-sectional study. BMC Med Educ 2018; 18:15. [PMID: 29334939 PMCID: PMC5769332 DOI: 10.1186/s12909-018-1117-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/26/2017] [Accepted: 01/05/2018] [Indexed: 05/15/2023]
Abstract
BACKGROUND Little information is currently available concerning young medical students desire to pursue a career in oncology, or their career expectations. METHODS This project is a cross-sectional epidemiological study. A voluntary and anonymous questionnaire was distributed to all young oncologists studying in France between the 2nd of October 2013 and the 23rd of February 2014. RESULTS The overall response rate was 75.6%. A total of 505 young oncologists completed the questionnaire. The main determining factors in the decision to practice oncology were the cross-sectional nature of the field (70.8%), the depth and variety of human relations (56.3%) and the multi-disciplinary field of work (50.2%). Most residents would like to complete a rotation outside of their assigned region (59.2%) or abroad (70.2%) in order to acquire additional expertise (67.7%). In addition, most interns would like to undertake a fellowship involving care, teaching and research in order to hone their skills (85.7%) and forge a career in public hospitals (46.4%). Career prospects mainly involve salaried positions in public hospitals. Many young oncologists are concerned about their professional future, due to the shortage of openings (40.8%), the workload (52.8%) and the lack of work-life balance (33.4%). CONCLUSIONS This investigation provides a comprehensive profile of the reasons young oncologists chose to pursue a career in oncology, and their career prospects.
Collapse
Affiliation(s)
- J. C. Faivre
- Academic Radiation Oncology & Brachytherapy Department, Lorraine Institute of Cancerology - Alexis-Vautrin Comprehensive Cancer Centre, 6 avenue de Bourgogne, 54519 Vandœuvre-lès-Nancy, France
- Radiation Oncology Department, University Hospital of Paris (Georges Pompidou European Hospital), 20 rue Leblanc, 75015 Paris, France
- Academic Department of Radiation Therapy & Brachytherapy, Lorraine Institute of Cancerology – Alexis-Vautrin CLCC [Centre de lutte contre le cancer – Cancer Centre] – Unicancer, 6 avenue de Bourgogne –CS 30 519, cedex F-54 511 Vandoeuvre-lès-Nancy, France
| | - J. E. Bibault
- French Society of Young Radiation Oncologists (SFjRO), Centre Antoine-Béclère, 45 rue des Saint Pères, 75005 Paris, France
- Radiation Oncology Department, University Hospital of Paris (Georges Pompidou European Hospital), 20 rue Leblanc, 75015 Paris, France
- Paris Descartes University, 12 rue de l’Ecole de médicine, 75006 Paris, France
| | - A. Bellesoeur
- Medical Oncology Department, University Hospital of Paris (Teaching Hospital Cochin), 27 rue du Faubourg Saint Jacques, 75014 Paris, France
- French Resident’s and Fellow’s Association for Teaching and Research in Oncology (AERIO), 149 avenue du Maine, 75014 Paris, France
| | - J. Salleron
- Biostatistics Department, Lorraine Institute of Cancerology - Alexis-Vautrin Comprehensive Cancer Centre, 6 avenue de Bourgogne, F-54519 Vandœuvre-lès-Nancy, France
| | - M. Wack
- Biostatistics and Epidemiology Department, University Hospital of Nancy, 9 avenue de la Forêt de Haye, 54505 Vandoeuvre-lès-nancy, France
| | - J. Biau
- French Society of Young Radiation Oncologists (SFjRO), Centre Antoine-Béclère, 45 rue des Saint Pères, 75005 Paris, France
- Radiation Oncology Department, Jean-Perrin Comprehensive Cancer Centre, 58 rue Montalembert, 63000 Clermont-Ferrand, France
- University of Auvergne, 28 place Henri Dunant, 63000 Clermont-Ferrand, France
| | - M. Cervellera
- French Society of Young Radiation Oncologists (SFjRO), Centre Antoine-Béclère, 45 rue des Saint Pères, 75005 Paris, France
- Radiation Oncology Department, Jean Godinot Comprehensive Cancer Centre, 1 rue du Général Koenig, 51726 Reims, France
| | - G. Janoray
- French Society of Young Radiation Oncologists (SFjRO), Centre Antoine-Béclère, 45 rue des Saint Pères, 75005 Paris, France
- S. Kaplan Cancer Centre, Radiation Oncology Department, University Hospital of Tours, 2 boulevard Tonnelé, 37000 Tours, France
| | - T. Leroy
- French Society of Young Radiation Oncologists (SFjRO), Centre Antoine-Béclère, 45 rue des Saint Pères, 75005 Paris, France
- Academic Radiation Oncology Department, Oscar Lambret Comprehensive Cancer Centre, 3 rue Frédéric Combemale, 59000 Lille, France
| | - N. Lescut
- French Society of Young Radiation Oncologists (SFjRO), Centre Antoine-Béclère, 45 rue des Saint Pères, 75005 Paris, France
- Radiation Oncology Department, University Hospital of Besançon, 3 boulevard Fleming, 25000 Besançon, France
| | - V. Martin
- French Society of Young Radiation Oncologists (SFjRO), Centre Antoine-Béclère, 45 rue des Saint Pères, 75005 Paris, France
- Radiation Oncology Department, University Hospital of Paris (Kremlin-Bicêtre Hospital), 78 rue du Général Leclerc, 94270 Paris, France
- Paris Sud University, 63 rue Gabriel Péri, 94276 Orsay, France
| | - S. Molina
- French Society of Young Radiation Oncologists (SFjRO), Centre Antoine-Béclère, 45 rue des Saint Pères, 75005 Paris, France
- Radiation Oncology Department, University Hospital of Poitiers, 2 rue de la Milétrie, 86021 Poitiers, France
| | - B. Pichon
- French Society of Young Radiation Oncologists (SFjRO), Centre Antoine-Béclère, 45 rue des Saint Pères, 75005 Paris, France
- Radiation Oncology Department, René-Gauducheau Comprehensive Cancer Centre, boulevard Jacques Monod, 44805 Nantes, Saint-Herblain France
| | - C. Teyssier
- French Society of Young Radiation Oncologists (SFjRO), Centre Antoine-Béclère, 45 rue des Saint Pères, 75005 Paris, France
- Radiation Oncology Department, University Hospital of Besançon, 3 boulevard Fleming, 25000 Besançon, France
| | - S. Thureau
- Radiation Oncology & Medical Physics Department, Henri-Becquerel Comprehensive Cancer Centre, rue d’Amiens, 76000 Rouen, France
- EA4108 QuantIf Litis, University of Rouen, 22 boulevard Gambetta, 76000 Rouen, France
| | - J. J. Mazeron
- Radiation Oncology Department, University Hospital of Paris (Pitié-Salpétrière Hospital), 83 boulevard de l’hôpital, 75013 Paris, France
- University Pierre et Marie Curie, 4 place Jussieu, 75005 Paris, France
| | - H. Roché
- Oncopole Toulouse, Claudius Regaud Comprehensive Cancer Centre, 1 avenue Irène Joliot-Curie, 31059 Toulouse, France
- University of Toulouse, 37 allée Jules Guesde, 36000 Toulouse, France
| | - S. Culine
- Medical Oncology Department, University Hospital of Paris (Saint-Louis Hospital), 1 avenue Claude Vellefaux, 75010 Paris, France
- Paris Diderot University, 16 rue Huchard, 75018 Paris, France
| |
Collapse
|
25
|
Besson N, Hennequin C, Guillerm S, Fumagalli I, Martin V, Michaud S, Texeira L, Quero L. Plesiobrachytherapy for chest wall recurrences of breast cancer after mastectomy and radiotherapy for breast cancer. Brachytherapy 2017; 17:425-431. [PMID: 29174938 DOI: 10.1016/j.brachy.2017.10.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2017] [Revised: 10/08/2017] [Accepted: 10/10/2017] [Indexed: 11/24/2022]
Abstract
PURPOSE The purpose of the study was to evaluate the results of high-dose-rate plesiobrachytherapy for local relapse after mastectomy and radiotherapy in terms of both local control and survival. METHODS We reviewed retrospectively 43 patients who experienced a chest wall relapse of breast cancer after local excision (22 patients) or not (21 patients). Patients were treated with an individually designed mold with four to six fractions of 3-6 Gy high-dose-rate brachytherapy, two fractions per week. Mean total dose was 24 Gy. RESULTS After surgical resection, the 3- and 5-year local control rates were 80% and 73%, respectively. For nonresectable patients, the overall response rate was 86%, and the 3-year infield local control and chest wall local control were 51% and 26%, respectively. The 5-year survival rate was 50.5% for the whole population, 62% after surgery, and 45.4% for irresectable patients. Acute Grade 2 or 3 toxicity occurred in 43% of the patients, resolving in a few days. Two patients had a local necrosis lasting 3 to 7 months. Late toxicity was observed in 5 patients. CONCLUSIONS High-dose-rate plesiobrachytherapy is a simple outpatient technique to treat chest wall local relapse of breast cancer. As a reirradiation technique, its tolerance is acceptable. This technique may obtain long-term local control after incomplete surgery; in case of nonresectable disease, a high response rate was observed, which might improve the quality of life of these patients.
Collapse
Affiliation(s)
- Nadia Besson
- Department of Radiation Oncology, Hôpital Saint-Louis, Paris, France
| | | | - Sophie Guillerm
- Department of Radiation Oncology, Hôpital Saint-Louis, Paris, France; Breast Disease Centre, Hôpital Saint-Louis, Paris, France
| | - Ingrid Fumagalli
- Department of Radiation Oncology, Hôpital Saint-Louis, Paris, France
| | - Valentine Martin
- Department of Radiation Oncology, Hôpital Saint-Louis, Paris, France
| | - Sophie Michaud
- Department of Radiation Oncology, Hôpital Saint-Louis, Paris, France
| | - Luis Texeira
- Breast Disease Centre, Hôpital Saint-Louis, Paris, France
| | - Laurent Quero
- Department of Radiation Oncology, Hôpital Saint-Louis, Paris, France
| |
Collapse
|
26
|
Almeras T, Schreiber P, Fournel S, Martin V, Nicolas CS, Fontaine C, Lesbros C, Gueguen S. Comparative efficacy of the Leucofeligen™ FeLV/RCP and Purevax™ RCP FeLV vaccines against infection with circulating feline Calicivirus. BMC Vet Res 2017; 13:300. [PMID: 29017551 PMCID: PMC5635571 DOI: 10.1186/s12917-017-1217-y] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2016] [Accepted: 10/03/2017] [Indexed: 11/17/2022] Open
Abstract
Background Feline calicivirus (FCV) is a common virus, found worldwide, mainly responsible for chronic ulceroproliferative faucitis and periodontitis. This virus has a high mutation rate, leading to the presence of numerous FCV strains in the field. The objectives of this study was to evaluate and compare the efficacy of two vaccines (Leucofeligen™ FeLV/RCP and Purevax™ RCP FeLV), which differ by their nature (live vs. inactivated) and the vaccinal strains, against circulating FCV strains. Thirty 9-week-old specific pathogen free (SPF) kittens were thus randomised into 3 groups and were either not vaccinated (control) or vaccinated (2 injections, 3 weeks apart) with one of the vaccines. Four weeks after the second injection of primary vaccination, the cats were inoculated with a pathogenic strain representative of the ones circulating in Europe (FCV-FR4_01) and followed for 2 weeks. Results After challenge, significant differences (p < 0.05) between control cats and cats vaccinated with Leucofeligen™ FeLV/RCP or Purevax™ RCP FeLV were observed for body weight variation, rectal temperature rise and maximum clinical scores, reflecting the intensity of the signs (83% and 67% lower in the respective vaccinated groups than in the control group). Significant differences were observed between the vaccinated groups, as cats vaccinated with Leucofeligen™ FeLV/RCP had a lower temperature rise (p < 0.05 at days post-challenge 3 to 5) and lower virus shedding titres (p < 0.05 at days post-challenge 8, 9 and 11) than cats vaccinated with Purevax™ RCP FeLV. Finally, only cats vaccinated with Leucofeligen™ FeLV/RCP had a significantly lower cumulative score, reflecting the intensity and duration of calicivirosis clinical signs, than the control cats (77% lower vs. 62% lower for cats vaccinated with Purevax™ RCP FeLV). Conclusions Both vaccines, Leucofeligen™ FeLV/RCP and Purevax™ RCP FeLV, were found to be efficacious in reducing clinical signs induced by FCV-FR4_01, a FCV strain representative of the circulating ones. However, cats vaccinated with Leucofeligen™ FeLV/RCP were able to control the infection more efficiently than those vaccinated with Purevax™ RCP FeLV, as evidenced by the shorter duration of clinical signs and lower viral titre in excretions.
Collapse
Affiliation(s)
- T Almeras
- Virbac, 13ème rue, LID, 06511, Carros, France
| | - P Schreiber
- Virbac, 13ème rue, LID, 06511, Carros, France
| | - S Fournel
- Virbac, 13ème rue, LID, 06511, Carros, France
| | - V Martin
- Virbac, 13ème rue, LID, 06511, Carros, France
| | - C S Nicolas
- Virbac, 13ème rue, LID, 06511, Carros, France
| | - C Fontaine
- Virbac, 13ème rue, LID, 06511, Carros, France.
| | - C Lesbros
- Virbac, 13ème rue, LID, 06511, Carros, France
| | - S Gueguen
- Virbac, 13ème rue, LID, 06511, Carros, France
| |
Collapse
|
27
|
Hennequin C, Fumagalli I, Martin V, Quero L. [Combination of radiotherapy and androgen deprivation therapy for localized prostate cancer]. Cancer Radiother 2017; 21:462-468. [PMID: 28870416 DOI: 10.1016/j.canrad.2017.07.045] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2017] [Accepted: 07/02/2017] [Indexed: 10/18/2022]
Abstract
Combination of radiotherapy and androgen deprivation is now considered as the standard of care for patients with a localized prostate cancer but poor prognosis factors. Two groups of randomized trials have led to this recommendation: some have compared radiotherapy alone versus hormonal treatment and radiotherapy: these trials demonstrated, now with a long follow-up, an improvement in 10-year survival for the combined treatment. Three recent trials compared androgen deprivation alone or combined with radiotherapy; a benefit in survival was also demonstrated in favour of the combination. Some questions remained concerning the optimal duration of hormonal treatment, in view of its potential side effects. Patients in the intermediate prognostic groups could receive a short-term androgen deprivation, but those with a high Gleason score must be treated with a long-term hormonal treatment. Modalities of radiotherapy, regarding volumes and dose must also be précised in the next years.
Collapse
Affiliation(s)
- C Hennequin
- Service de cancérologie-radiothérapie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75475 Paris, France.
| | - I Fumagalli
- Service de cancérologie-radiothérapie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75475 Paris, France
| | - V Martin
- Service de cancérologie-radiothérapie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75475 Paris, France
| | - L Quero
- Service de cancérologie-radiothérapie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75475 Paris, France
| |
Collapse
|
28
|
Rossignon F, Martin V, Salles J, Patrac V, Le Bacquer O, Berry A, Pion A, Giraudet C, Montaurier C, Ratel S, François B, Roussillat C, Walrand S, Combe K, Domingues Faria C, Boirie Y, Guillet C. L’apport protéique a-t-il une influence sur la composition corporelle et la fonctionnalité musculaire en situation de surnutrition lipidique ? NUTR CLIN METAB 2017. [DOI: 10.1016/j.nupar.2017.06.084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
29
|
Rodriguez-Blanco J, Pednekar L, Penas C, Li B, Martin V, Long J, Lee E, Weiss WA, Rodriguez C, Mehrdad N, Nguyen DM, Ayad NG, Rai P, Capobianco AJ, Robbins DJ. Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma. Oncogene 2017; 36:6306-6314. [PMID: 28714964 DOI: 10.1038/onc.2017.232] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2015] [Revised: 06/02/2017] [Accepted: 06/05/2017] [Indexed: 12/24/2022]
Abstract
The SMOOTHENED inhibitor vismodegib is FDA approved for advanced basal cell carcinoma (BCC), and shows promise in clinical trials for SONIC HEDGEHOG (SHH)-subgroup medulloblastoma (MB) patients. Clinical experience with BCC patients shows that continuous exposure to vismodegib is necessary to prevent tumor recurrence, suggesting the existence of a vismodegib-resistant reservoir of tumor-propagating cells. We isolated such tumor-propagating cells from a mouse model of SHH-subgroup MB and grew them as sphere cultures. These cultures were enriched for the MB progenitor marker SOX2 and formed tumors in vivo. Moreover, while their ability to self-renew was resistant to SHH inhibitors, as has been previously suggested, this self-renewal was instead WNT-dependent. We show here that loss of Trp53 activates canonical WNT signaling in these SOX2-enriched cultures. Importantly, a small molecule WNT inhibitor was able to reduce the propagation and growth of SHH-subgroup MB in vivo, in an on-target manner, leading to increased survival. Our results imply that the tumor-propagating cells driving the growth of bulk SHH-dependent MB are themselves WNT dependent. Further, our data suggest combination therapy with WNT and SHH inhibitors as a therapeutic strategy in patients with SHH-subgroup MB, in order to decrease the tumor recurrence commonly observed in patients treated with vismodegib.
Collapse
Affiliation(s)
- J Rodriguez-Blanco
- Molecular Oncology Program, The DeWitt Daughtry Family Department of Surgery, University of Miami, Miller School of Medicine, Miami, FL, USA
| | - L Pednekar
- Molecular Oncology Program, The DeWitt Daughtry Family Department of Surgery, University of Miami, Miller School of Medicine, Miami, FL, USA
| | - C Penas
- Center for Therapeutic Innovation, Department of Psychiatry and Behavioral Sciences, University of Miami, Miller School of Medicine, Miami, FL, USA
| | - B Li
- Molecular Oncology Program, The DeWitt Daughtry Family Department of Surgery, University of Miami, Miller School of Medicine, Miami, FL, USA
| | - V Martin
- Morphology and Cell Biology Department, University of Oviedo, Asturias, Spain
| | - J Long
- Molecular Oncology Program, The DeWitt Daughtry Family Department of Surgery, University of Miami, Miller School of Medicine, Miami, FL, USA
| | - E Lee
- Department of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, USA
| | - W A Weiss
- Department of Neurobiology, University of California, San Francisco, CA, USA
| | - C Rodriguez
- Morphology and Cell Biology Department, University of Oviedo, Asturias, Spain
| | - N Mehrdad
- Department of Pathology, University of Miami, Miller School of Medicine, Miami, FL, USA
| | - D M Nguyen
- Division of Cardiothoracic Surgery, The DeWitt Daughtry Family Department of Surgery, University of Miami, Miller School of Medicine, Miami, FL, USA.,Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA
| | - N G Ayad
- Center for Therapeutic Innovation, Department of Psychiatry and Behavioral Sciences, University of Miami, Miller School of Medicine, Miami, FL, USA.,Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA
| | - P Rai
- Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.,Department of Medicine, University of Miami, Miller School of Medicine, Miami, FL, USA
| | - A J Capobianco
- Molecular Oncology Program, The DeWitt Daughtry Family Department of Surgery, University of Miami, Miller School of Medicine, Miami, FL, USA.,Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA
| | - D J Robbins
- Molecular Oncology Program, The DeWitt Daughtry Family Department of Surgery, University of Miami, Miller School of Medicine, Miami, FL, USA.,Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA
| |
Collapse
|
30
|
Ferguson S, Gotlieb W, Gien L, Giede C, Samouelian V, Steed H, Renkosinski B, Abitbol J, Warkus T, Le T, Martin V, Panzarella T, Covens A, Bernardini M. GOC2: A multicenter prospective trial comparing open, laparoscopic and robotic surgical outcomes in women with endometrial cancer. Part B: Patient-reported outcomes. Gynecol Oncol 2017. [DOI: 10.1016/j.ygyno.2017.03.079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
31
|
Dávila-Batista V, Carriedo D, Díez F, Pueyo Bastida A, Martínez Durán B, Martin V. [Estimation of the population attributable fraction due to obesity in hospital admissions for flu valued according to Body Mass Index (BMI) and CUN-BAE]. Semergen 2017; 44:100-106. [PMID: 28506756 DOI: 10.1016/j.semerg.2017.01.011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2016] [Revised: 01/11/2017] [Accepted: 01/12/2017] [Indexed: 11/17/2022]
Abstract
INTRODUCTION The obesity pandemic together with the influenza pandemic could lead to a significant burden of disease. The body mass index (BMI) does not discriminate obesity appropriately. The CUN-BAE has recently been used as an estimate of body fatness for Caucasians, including BMI, gender, and age. The aim of this study is to assess the population attributable fraction of hospital admissions due to influenza, due to the body fatness measured with the BMI, and the CUN-BAE. METHODS A multicentre study was conducted using matched case-controls. Cases were hospital admissions with the influenza confirmed by the RT-PCR method between 2009 and 2011. The risk of hospital admission and the population attribuible fraction were calculated using the BMI or the CUN-BAE for each adiposity category in a conditional logical regression analysis adjusted for confounding variables. The analyzes were estimated in the total sample, in unvaccinated people, and those less than 65 years-old. RESULTS A total of 472 hospitalised cases and 493 controls were included in the study. Compared to normal weight, the aOR of influenza hospital admissions increases with each level of BMI (aOR=1.26; 2.06 and 11.64) and CUN-BAE (aOR=2.78; 4.29; 5.43 and 15.18). The population attributable fraction of influenza admissions using CUN-BAE is 3 times higher than that estimated with BMI (0,72 vs. 0,27), with the differences found being similar the non-vaccinated and under 65 year-olds. CONCLUSION The BMI could be underestimating the burden of disease attributable to obesity in individuals hospitalised with influenza. There needs to be an appropriate assessment of the impact of obesity and vaccine recommendation criteria.
Collapse
Affiliation(s)
- V Dávila-Batista
- Grupo de Investigación interacciones gen-ambiente y salud (GIGAS), Universidad de León, León, España
| | - D Carriedo
- Complejo Asistencial Universitario de León, León, España
| | - F Díez
- Complejo Asistencial Universitario de León, León, España
| | | | | | - V Martin
- Grupo de Investigación interacciones gen-ambiente y salud (GIGAS), Universidad de León, León, España; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, España.
| |
Collapse
|
32
|
Guillerm S, Bourstyn E, Itti R, Fumagalli I, Martin V, Cahen-Doidy L, Quero L, Giacchetti S, Cuvier C, Espié M, Hennequin C. EP-1150: Preliminary results of Intra-Operative RadioTherapy in old women with good prognostic features. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)31586-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
33
|
Verney J, Martin V, Ratel S, Chavanelle V, Bargetto M, Etienne M, Chaplais E, Le Ruyet P, Bonhomme C, Combaret L, Guillet C, Boisseau N, Sirvent P, Dardevet D. Soluble Milk Proteins Improve Muscle Mass Recovery after Immobilization-Induced Muscle Atrophy in Old Rats but Do not Improve Muscle Functional Property Restoration. J Nutr Health Aging 2017; 21:1133-1141. [PMID: 29188872 DOI: 10.1007/s12603-016-0855-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
OBJECTIVES Effect of 3 different dairy protein sources on the recovery of muscle function after limb immobilization in old rats. DESIGN Longitudinal animal study. SETTING Institut National de la Recherche Agronomique (INRA). The study took part in a laboratory setting. INTERVENTION Old rats were subjected to unilateral hindlimb immobilization for 8 days and then allowed to recover with 3 different dietary proteins: casein, soluble milk proteins or whey proteins for 49 days. MEASUREMENTS Body weight, muscle mass, muscle fibre size, isometric, isokinetic torque, muscle fatigability and muscle oxidative status were measured before and at the end of the immobilization period and during the recovery period i.e 7, 21, 35 and 49 days post immobilization. RESULTS In contrast to the casein diet, soluble milk proteins and whey proteins were efficient to favor muscle mass recovery after cast immobilization during aging. By contrast, none of the 3 diary proteins was able to improve muscle strength, power and fatigability showing a discrepancy between the recovery of muscle mass and function. However, the soluble milk proteins allowed a better oxidative capacity in skeletal muscle during the rehabilitation period. CONCLUSION Whey proteins and soluble milk proteins improve muscle mass recovery after immobilization-induced muscle atrophy in old rats but do not allow muscle functional property restoration.
Collapse
Affiliation(s)
- J Verney
- Dominique Dardevet, INRA, Unité de Nutrition Humaine (UNH, UMR 1019), CRNH Auvergne, France,
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Chabert I, E. Barat, Dhermain F, Poisson F, Ammari S, Martin V, Buvat I, D. Lazaro, Deutsch E, Robert C. 12. Analysis of the impact of rCBV map threshold to predict tumor recurrence in high-grade gliomas. Phys Med 2016. [DOI: 10.1016/j.ejmp.2016.11.063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
35
|
Chabert I, Belladjou I, Poisson F, Dhermain F, Martin V, Ammari S, Vauclin S, Pineau P, Buvat I, Deutsch E, Robert C. EP-1875: Correlation between MRI-based hyper-perfused areas and tumor recurrence in high-grade gliomas. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)33126-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
36
|
Stragier E, Martin V, Davenas E, Poilbout C, Mongeau R, Corradetti R, Lanfumey L. Brain plasticity and cognitive functions after ethanol consumption in C57BL/6J mice. Transl Psychiatry 2015; 5:e696. [PMID: 26670281 PMCID: PMC5068583 DOI: 10.1038/tp.2015.183] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/11/2015] [Revised: 09/23/2015] [Accepted: 10/09/2015] [Indexed: 12/20/2022] Open
Abstract
Acute or chronic administrations of high doses of ethanol in mice are known to produce severe cognitive deficits linked to hippocampal damage. However, we recently reported that chronic and moderate ethanol intake in C57BL/6J mice induced chromatin remodeling within the Bdnf promoters, leading to both enhanced brain-derived neurotrophic factor (BDNF) expression and hippocampal neurogenesis under free-choice protocol. We performed here a series of cellular and behavioral studies to analyze the consequences of these modifications. We showed that a 3-week chronic free-choice ethanol consumption in C57BL/6J mice led to a decrease in DNA methylation of the Bdnf gene within the CA1 and CA3 subfields of the hippocampus, and upregulated hippocampal BDNF signaling pathways mediated by ERK, AKT and CREB. However, this activation did not affect long-term potentiation in the CA1. Conversely, ethanol intake impaired learning and memory capacities analyzed in the contextual fear conditioning test and the novel object recognition task. In addition, ethanol increased behavioral perseveration in the Barnes maze test but did not alter the mouse overall spatial capacities. These data suggested that in conditions of chronic and moderate ethanol intake, the chromatin remodeling leading to BDNF signaling upregulation is probably an adaptive process, engaged via epigenetic regulations, to counteract the cognitive deficits induced by ethanol.
Collapse
Affiliation(s)
- E Stragier
- Centre de Psychiatrie et Neurosciences, INSERM UMR 894, Paris, France
- Université Paris Descartes, UMR S894, Paris, France
| | - V Martin
- Centre de Psychiatrie et Neurosciences, INSERM UMR 894, Paris, France
- Université Paris Descartes, UMR S894, Paris, France
| | - E Davenas
- Centre de Psychiatrie et Neurosciences, INSERM UMR 894, Paris, France
- Université Paris Descartes, UMR S894, Paris, France
| | - C Poilbout
- Centre de Psychiatrie et Neurosciences, INSERM UMR 894, Paris, France
- Université Paris Descartes, UMR S894, Paris, France
| | - R Mongeau
- Université Paris Descartes, UMR S894, Paris, France
- Pharmacologie de la circulation cérébrale EA 4475, Faculté de pharmacie Université Paris Descartes, Paris, France
| | - R Corradetti
- Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy
| | - L Lanfumey
- Centre de Psychiatrie et Neurosciences, INSERM UMR 894, Paris, France
- Université Paris Descartes, UMR S894, Paris, France
| |
Collapse
|
37
|
Martin V, Cuenca X, Lopez S, Albertini AF, Lang P, Simon JM, Hémery CG, Feuvret L, Mazeron JJ. Iris metastasis from prostate carcinoma: A case report and review of the literature. Cancer Radiother 2015; 19:331-3. [DOI: 10.1016/j.canrad.2014.12.008] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2014] [Revised: 12/15/2014] [Accepted: 12/24/2014] [Indexed: 11/25/2022]
|
38
|
Bartels A, Martin V, Bidoli E, Steigmeier-Raith S, Brühschwein A, Reese S, Köstlin R, Erhard M. Brachycephalic problems of pugs relevant to animal welfare. Anim Welf 2015. [DOI: 10.7120/09627286.24.3.327] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
39
|
Kamsu-Kom L, Bidault F, Mazeron R, Baratiny C, Martin V, Maroun P, Dumas I, Guemnie-Tafo A, Martinetti F, Gerbaulet A, Chargari C, Haie-Meder C. Clinical Experience with Pulse Dose Rate Brachytherapy for Conservative Treatment of Penile Carcinoma and Comparison with Historical Data of Low Dose Rate Brachytherapy. Clin Oncol (R Coll Radiol) 2015; 27:387-93. [DOI: 10.1016/j.clon.2015.03.010] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2014] [Revised: 03/11/2015] [Accepted: 03/26/2015] [Indexed: 10/23/2022]
|
40
|
Zghal F, Cottin F, Kenoun I, Rebaï H, Moalla W, Dogui M, Tabka Z, Martin V. Improved tolerance of peripheral fatigue by the central nervous system after endurance training. Eur J Appl Physiol 2015; 115:1401-15. [PMID: 25681110 DOI: 10.1007/s00421-015-3123-y] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2014] [Accepted: 02/03/2015] [Indexed: 11/28/2022]
Abstract
PURPOSE The purposes of this study were to evaluate the effect of endurance training on central fatigue development and recovery. METHODS A control group was compared to a training group, which followed an 8-week endurance-training program, consisting in low-force concentric and isometric contractions. Before (PRE) and after (POST) the training period, neuromuscular function of the knee extensor (KE) muscles was evaluated before, immediately after and during 33 min after an exhausting submaximal isometric task at 15 % of the maximal voluntary contraction (MVC) force. After training, the trained group performed another test at iso-time, i.e., with the task maintained until the duration completed before training was matched (POST2). The evaluation of neuromuscular function consisted in the determination of the voluntary activation level during MVCs, from peripheral nerve electrical (VAPNS) and transcranial magnetic stimulations (VATMS). The amplitude of the potentiated twitch (Pt), the evoked [motor evoked potentials, cortical silent period (CSP)] and voluntary EMG activities were also recorded on the KE muscles. RESULTS Before training, the isometric task induced significant reductions of VAPNS, VATMS and Pt, and an increased CSP. The training period induced a threefold increase of exercise duration, delayed central fatigue appearance, as illustrated by the absence of modification of VAPNS, VATMS and CSP after POST2. At POST, central fatigue magnitude and recovery were not modified but Pt reduction was greater. CONCLUSION These results suggest that central fatigue partially adapts to endurance training. This adaptation principally translates into improved tolerance of peripheral fatigue by the central nervous system.
Collapse
Affiliation(s)
- F Zghal
- UBIAE (INSERM U902), Faculty of Sport Sciences, Val d'Essonne University, Evry, France
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Bourourou M, Holzinger M, Elouarzaki K, Le Goff A, Bossard F, Rossignol C, Djurado E, Martin V, Curtil D, Chaussy D, Maaref A, Cosnier S. Laccase wiring on free-standing electrospun carbon nanofibres using a mediator plug. Chem Commun (Camb) 2015; 51:14574-7. [DOI: 10.1039/c5cc03906a] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The enzyme laccase was wired on a free-standing electrospun carbon fiber mat using a cross-linker plug based on the pyrene modified electron shuttle ABTS.
Collapse
Affiliation(s)
- M. Bourourou
- Univ. Grenoble Alpes - CNRS
- DCM UMR 5250
- F-38000 Grenoble
- France
- Laboratoire des Interfaces et des Matériaux Avancés
| | - M. Holzinger
- Univ. Grenoble Alpes - CNRS
- DCM UMR 5250
- F-38000 Grenoble
- France
| | - K. Elouarzaki
- Univ. Grenoble Alpes - CNRS
- DCM UMR 5250
- F-38000 Grenoble
- France
| | - A. Le Goff
- Univ. Grenoble Alpes - CNRS
- DCM UMR 5250
- F-38000 Grenoble
- France
| | - F. Bossard
- Univ. Grenoble Alpes – CNRS
- LRP
- F-38000 Grenoble
- France
| | | | - E. Djurado
- Univ. Grenoble Alpes
- LEPMI
- F-38000 Grenoble
- France
| | - V. Martin
- Univ. Grenoble Alpes
- LEPMI
- F-38000 Grenoble
- France
| | - D. Curtil
- LGP2 (Laboratory of Pulp and Paper Science and Graphic Arts)
- Grenoble INP-Pagora/CNRS UMR
- 38402 Grenoble
- France
| | - D. Chaussy
- LGP2 (Laboratory of Pulp and Paper Science and Graphic Arts)
- Grenoble INP-Pagora/CNRS UMR
- 38402 Grenoble
- France
| | - A. Maaref
- Laboratoire des Interfaces et des Matériaux Avancés
- Faculté des Sciences de Monastir-Université de Monastir
- Tunisia
| | - S. Cosnier
- Univ. Grenoble Alpes - CNRS
- DCM UMR 5250
- F-38000 Grenoble
- France
| |
Collapse
|
42
|
Rodriguez-Blanco J, Bin L, Martin V, Lee E, Rodriguez C, Capobianco A, Robbins DJ. SC-28 * NOVEL INHIBITORS ON HEDGEHOG PATHWAY TO PREVENT MEDULLOBLASTOMA RELAPSE. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou275.28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
43
|
Lechauve J, Perrault H, Aguilaniu B, Isner-Horobeti M, Martin V, Coudeyre E, Richard R. Breathing patterns during eccentric exercise. Respir Physiol Neurobiol 2014; 202:53-8. [DOI: 10.1016/j.resp.2014.07.007] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2014] [Revised: 07/05/2014] [Accepted: 07/08/2014] [Indexed: 11/29/2022]
|
44
|
Mazeron R, Castelnau-Marchand P, Dumas I, Martin V, Kom LK, Farha G, Martinetti F, Tailleur A, Lefkopopoulos D, Haie-Méder C. Impact de l’étalement et de l’escalade de dose sur le contrôle local des cancers du col de l’utérus après chimioradiothérapie suivie de curiethérapie guidée par l’image. Cancer Radiother 2014. [DOI: 10.1016/j.canrad.2014.07.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
45
|
Riva A, Mozzi A, Forcella M, Difrancesco C, Molinari F, Papini N, Bernasconi B, Martin V, Mazzucchelli L, Monti E, Fusi P, Frattini M. Neu3 Activity Enhances Egfr Activation Without Affecting Egfr Expression. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu359.26] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
46
|
Mazeron R, Dumas I, Martin V, Martinetti F, Benhabib-Boukhelif W, Gensse MC, Chargari C, Guemnie-Tafo A, Haie-Méder C. [Pulsed-dose rate brachytherapy in cervical cancers: why, how?]. Cancer Radiother 2014; 18:447-51. [PMID: 25155782 DOI: 10.1016/j.canrad.2014.06.010] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2014] [Revised: 06/24/2014] [Accepted: 06/26/2014] [Indexed: 10/24/2022]
Abstract
The end of the production of 192 iridium wires terminates low dose rate brachytherapy and requires to move towards pulsed-dose rate or high-dose rate brachytherapy. In the case of gynecological cancers, technical alternatives exist, and many teams have already taken the step of pulsed-dose rate for scientific reasons. Using a projector source is indeed a prerequisite for 3D brachytherapy, which gradually installs as a standard treatment in the treatment of cervical cancers. For other centers, this change implies beyond investments in equipment and training, organizational consequences to ensure quality.
Collapse
Affiliation(s)
- R Mazeron
- Département d'oncologie-radiothérapie, institut de cancérologie Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France.
| | - I Dumas
- Département de physique médicale, institut de cancérologie Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France
| | - V Martin
- Département d'oncologie-radiothérapie, institut de cancérologie Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France
| | - F Martinetti
- Département de physique médicale, institut de cancérologie Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France
| | - W Benhabib-Boukhelif
- Département de physique médicale, institut de cancérologie Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France
| | - M-C Gensse
- Département d'oncologie-radiothérapie, institut de cancérologie Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France
| | - C Chargari
- Département d'oncologie-radiothérapie, institut de cancérologie Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France
| | - A Guemnie-Tafo
- Département de physique médicale, institut de cancérologie Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France
| | - C Haie-Méder
- Département d'oncologie-radiothérapie, institut de cancérologie Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France
| |
Collapse
|
47
|
Bibault JE, Leroy T, Blanchard P, Biau J, Cervellera M, Diaz O, Faivre JC, Fumagalli I, Lescut N, Martin V, Pichon B, Riou O, Thureau S, Giraud P. Mobile technology and social media in the clinical practice of young radiation oncologists: results of a comprehensive nationwide cross-sectional study. Int J Radiat Oncol Biol Phys 2014; 90:231-7. [PMID: 24986747 DOI: 10.1016/j.ijrobp.2014.05.012] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2014] [Revised: 04/24/2014] [Accepted: 05/11/2014] [Indexed: 10/25/2022]
Abstract
PURPOSE Social media and mobile technology are transforming the way in which young physicians are learning and practicing medicine. The true impact of such technologies has yet to be evaluated. METHODS AND MATERIALS We performed a nationwide cross-sectional survey to better assess how young radiation oncologists used these technologies. An online survey was sent out between April 24, 2013, and June 1, 2013. All residents attending the 2013 radiation oncology French summer course were invited to complete the survey. Logistic regressions were performed to assess predictors of use of these tools in the hospital on various clinical endpoints. RESULTS In all, 131 of 140 (93.6%) French young radiation oncologists answered the survey. Of these individuals, 93% owned a smartphone and 32.8% owned a tablet. The majority (78.6%) of the residents owning a smartphone used it to work in their department. A total of 33.5% had more than 5 medical applications installed. Only 60.3% of the residents verified the validity of the apps that they used. In all, 82.9% of the residents had a social network account. CONCLUSIONS Most of the residents in radiation oncology use their smartphone to work in their department for a wide variety of tasks. However, the residents do not consistently check the validity of the apps that they use. Residents also use social networks, with only a limited impact on their relationship with their patients. Overall, this study highlights the irruption and the risks of new technologies in the clinical practice and raises the question of a possible regulation of their use in the hospital.
Collapse
Affiliation(s)
- Jean-Emmanuel Bibault
- Academic Radiation Oncology Department, Oscar Lambret Center, Lille, France; French Society of Young Radiation Oncologists (SFjRO), Centre Antoine-Béclère, Paris, France.
| | - Thomas Leroy
- Academic Radiation Oncology Department, Oscar Lambret Center, Lille, France; French Society of Young Radiation Oncologists (SFjRO), Centre Antoine-Béclère, Paris, France
| | - Pierre Blanchard
- Academic Radiation Oncology Department, Gustave Roussy Institute, Villejuif Cedex, France; Biostatistics and Epidemiology Department, Gustave Roussy, Villejuif Cedex, France
| | - Julian Biau
- Radiation Oncology Department, Jean-Perrin Center, Clermont-Ferrand cedex, France; French Society of Young Radiation Oncologists (SFjRO), Centre Antoine-Béclère, Paris, France
| | - Mathilde Cervellera
- Radiation Oncology Department, Jean-Godinot Center, Reims, France; French Society of Young Radiation Oncologists (SFjRO), Centre Antoine-Béclère, Paris, France
| | - Olivia Diaz
- Radiation Oncology Department, Lyon Sud University Hospital, Pierre-Bénite Cedex, France; French Society of Young Radiation Oncologists (SFjRO), Centre Antoine-Béclère, Paris, France
| | - Jean Christophe Faivre
- Academic Radiation Oncology & Brachytherapy Departement, Alexis-Vautrin Center, Avenue de Bourgogne, 54511 Vandœuvre-lès-Nancy, France; French Society of Young Radiation Oncologists (SFjRO), Centre Antoine-Béclère, Paris, France
| | - Ingrid Fumagalli
- Academic Radiation Oncology Department, Oscar Lambret Center, Lille, France; French Society of Young Radiation Oncologists (SFjRO), Centre Antoine-Béclère, Paris, France
| | - Nicolas Lescut
- Radiation Oncology Department, BesanÇon University Hospital, BesanÇon Cedex, France; French Society of Young Radiation Oncologists (SFjRO), Centre Antoine-Béclère, Paris, France
| | - Valentine Martin
- Radiation Oncology Department, Gustave Roussy Institute, Villejuif Cedex, France; French Society of Young Radiation Oncologists (SFjRO), Centre Antoine-Béclère, Paris, France
| | - Baptiste Pichon
- Radiation Oncology Department, René-Gauducheau Center, Saint-Herblain, France; French Society of Young Radiation Oncologists (SFjRO), Centre Antoine-Béclère, Paris, France
| | - Olivier Riou
- Radiation Oncology Department, Montpellier Cancer Institute-Val d'Aurelle, parc Euromédecine, Montpellier Cedex, France; French Society of Young Radiation Oncologists (SFjRO), Centre Antoine-Béclère, Paris, France
| | - Sébastien Thureau
- Radiation Oncology & Medical Physics Department, QuantIf, Litis, EA4108, Centre Henri-Becquerel, Rouen, France; French Society of Young Radiation Oncologists (SFjRO), Centre Antoine-Béclère, Paris, France
| | - Philippe Giraud
- Radiation Oncology Department, Hôpital Européen Georges Pompidou, Paris Descartes University, Paris, France; French Society of Radiation Oncologists (SFRO), Paris, France
| |
Collapse
|
48
|
Feuvret L, Vinchon S, Martin V, Lamproglou I, Halley A, Calugaru V, Chea M, Valéry CA, Simon JM, Mazeron JJ. Stereotactic radiotherapy for large solitary brain metastases. Cancer Radiother 2014; 18:97-106. [PMID: 24439342 DOI: 10.1016/j.canrad.2013.12.003] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2013] [Revised: 12/02/2013] [Accepted: 12/04/2013] [Indexed: 10/25/2022]
Abstract
PURPOSE To assess effectiveness and toxicity levels of stereotactic radiation therapy without whole brain radiation therapy in patients with solitary brain metastases larger than 3cm. PATIENTS AND METHODS Between June 2007 and March 2009, 12 patients received fractionated stereotactic radiation therapy and 24 patients underwent stereotactic radiosurgery. For the fractionated stereotactic radiation therapy group, 3×7.7Gy were delivered to the planning target volume (PTV); median volume and diameter were 29.4 cm(3) and 4.4cm, respectively. For the stereotactic radiosurgery group, 14Gy were delivered to the PTV; median volume and diameter were 15.6 cm(3) and 3.7cm, respectively. RESULTS Median follow-up was 218 days. For the fractionated stereotactic radiation therapy group, local control rates were 100% at 360 days and 64% at 720 days; for the stereotactic radiosurgery group, rates were 58% at 360 days and 48% at 720 days (P=0.06). Median survival time was 504 days for the fractionated stereotactic radiation therapy group and 164 days for the stereotactic radiosurgery group (P=0.049). Two cases of grade 2 toxicity were observed in the fractionated stereotactic radiation therapy group, and 6 cases of grade 1-2 toxicity, in the stereotactic radiosurgery group. CONCLUSIONS This study provides data to support that fractionated stereotactic radiation therapy without whole brain radiation therapy with a margin dose of 3 fractions of 7.7Gy for treatment of solitary large brain metastases is efficient and well-tolerated. Because of the significant improvement in overall survival, this schedule should be assessed in a randomized trial.
Collapse
Affiliation(s)
- L Feuvret
- Centre des tumeurs, groupe Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France.
| | - S Vinchon
- Centre Paul-Papin, 2, rue Moll, 49100 Angers cedex, France
| | - V Martin
- Centre des tumeurs, groupe Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France
| | - I Lamproglou
- Centre des tumeurs, groupe Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France
| | - A Halley
- Centre des tumeurs, groupe Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France
| | - V Calugaru
- Centre de protonthérapie d'Orsay (CPO), institut Curie, bâtiment 101, campus universitaire, 91898 Orsay cedex, France
| | - M Chea
- Centre des tumeurs, groupe Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France
| | - C A Valéry
- Unité de Gamma-Knife, groupe Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France
| | - J-M Simon
- Centre des tumeurs, groupe Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France
| | - J-J Mazeron
- Centre des tumeurs, groupe Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France
| |
Collapse
|
49
|
Zghal F, Martin V, Thorkani A, Arnal PJ, Tabka Z, Cottin F. Effects of endurance training on the maximal voluntary activation level of the knee extensor muscles. Eur J Appl Physiol 2013; 114:683-93. [PMID: 24368553 DOI: 10.1007/s00421-013-2793-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2013] [Accepted: 12/06/2013] [Indexed: 10/25/2022]
Abstract
PURPOSE The aim of this study was to investigate the neural adaptations to endurance training, and more specifically the adaptation of the cortical voluntary activation of the knee extensor (KE) muscles. METHODS Sixteen sedentary men were randomly allocated into an endurance training (n = 8) or a control group (n = 8). All subjects performed a maximal aerobic speed test (MAS) before and immediately after the training period. Training lasted 8 weeks and was based on endurance running. During Pre- and Post-training testing sessions, maximal voluntary contraction (MVC) was measured and voluntary activation (VA) was calculated via peripheral nerve (PNS) and transcranial magnetic stimulations (TMS) superimposed to MVC. Electromyographic activity (EMG) of the KE muscles was also measured during MVC, PNS (M-wave) and TMS (motor evoked potentials-MEP). The cortical silent period following TMS was also assessed. RESULTS Despite a significant improvement in endurance running performance, as suggested by the increase of MAS in the training group (Pre 15.4 ± 1.6 vs. Post 16.4 ± 1.6 km·h(-1)), endurance training did not affect MVC or VA as measured with PNS and TMS. Similarly, the EMG of KE muscles during MVC did not show any significant changes. Furthermore, the MEP amplitude and the duration of the silent period also remained unchanged after endurance training. CONCLUSIONS The present study suggests an 8-week endurance-training program does not generate adaptations of neural factors in sedentary subjects.
Collapse
Affiliation(s)
- F Zghal
- UBIAE (INSERM U902), Faculty of Sport Sciences, Val d'Essonne University, Evry, France
| | | | | | | | | | | |
Collapse
|
50
|
Kokotos G, Martin V, Constantinou-Kokotou V, Gibbons WA. Synthesis of medicinally useful lipidicα-amino acids, 2-amino alcohols and diamines. Amino Acids 2013; 11:329-43. [PMID: 24178720 DOI: 10.1007/bf00807940] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/1996] [Accepted: 04/28/1996] [Indexed: 11/27/2022]
Abstract
The lipidicα-amino acids (LAAs) are non-naturalα-amino acids with saturated or unsaturated long aliphatic side chains. LAAs and their derivatives (lipid mimetics) together with the lipidic peptides represent a class of compounds which combine structural features of lipids with those of amino acids and peptides. Racemic LAAs may be prepared by classical methods and resolved by chemical or enzymatic methods. LAA amides and esters with saturated or unsaturated long chain amines and alcohols respectively, as well as lipidic dipeptide derivatives inhibit both pancreatic and human platelet phospholipase A2. Lipophilic peptide derivatives are inhibitors of human neutrophil elastase. LAAs and their oligomers have been used as drug delivery system. A Lipid-Core-Peptide system has been designed and used as a combined adjuvant-carrier-vaccine system. A variety of lipid mimetics such as lipidic 2-amino alcohols, lipidic 1,2- and 1,3-diamines have been prepared based upon LAAs. Some of them are potent inhibitors of phospholipase A2. A general approach to enantioselective synthesis of LAAs and lipid mimetics is based on the oxidative cleavage of 3-amino-1,2-diols obtained by the regioselective opening of enantiomerically enriched long chain 2,3-epoxy alcohols.
Collapse
Affiliation(s)
- G Kokotos
- Laboratory of Organic Chemistry, Department of Chemistry, University of Athens, Panepistimiopolis, GR-15771, Athens, Greece
| | | | | | | |
Collapse
|